|
Archive 2008
CEDAC made three new recommendations on Dec 17, 2008: Xarelto, Volibris and Truvada
CEDAC made two new recommendations on Nov 12, 2008: Celsentri and Omnaris
Access to New Medicines in Canada: A Look at CDR Reviewed Products
CEDAC made two positive recommendations on Oct 16, 2008: Humira and Stalevo
Updated List of Medications
Competitive Agreement Ontario
Brogan Inc. entered into an agreement with Rotman School of Management
Recent Publications: Effect of Cost-Sharing on Use of Asthma Medication in Children
Provincial Formulary Updates
PMPRB News - Regulations
CEDAC made three new recommendations on Dec 17, 2008: Xarelto, Volibris and Truvada
December 23, 2008:
Xarelto (rivaroxaban) by Bayer Inc. obtained a positive CEDAC listing recommendation from the NEW-Pre NOC pilot project. Canada is the first country to approve Xarelto, the first in a new class of anticoagulants, for the prevention of venous thromboembolic events (VTE), or blood clots, in patients who have undergone elective total hip or total knee replacement surgery.
Xarelto is associated with better clinical outcomes and lower overall costs relative to comparators. The daily cost of Xarelto is $9.90; enoxaparin costs $12.06 (30mg twice daily) and fondaparinux costs $15.08 per day.
Volibris (ambrisentan) by GlaxoSmithKline Inc. is for treatment of pulmonary arterial hypertension (PAH) in patients with WHO class II and III symptoms.
CEDAC’s positive listing recommendation was based on significantly better clinical outcomes compared with placebo and slightly lower price compared with selected comparators (e.g., bosentan).
Volibris is the third product reviewed by CEDAC for the indication of PAH (WHO class II and III). The other two are Revatio (positively recommended) and Thelin (negatively recommended).
The HIV drug Truvada (emtricitabine/tenofovir disoproxil fumarate) was submitted for Advice and resulted in a positive CEDAC recommendation. Truvada has been positively recommended before, but the Committee felt the Truvada recommendation should be congruent with Atripla, therefore superseded the recommendation reasons issued on October 25, 2006 with the one issued on December 17, 2008.
CDR Activity as of Dec 17, 2008 |
Number of CDR Submissions |
146 |
| Number of CDR Completed Submissions |
125 |
Number of CDR Active Submissions |
12 |
Number of CDR Submissions Withdrawn/Suspended |
9 |
| |
Number of CEDAC Recommendations |
121 |
Number of Positive CEDAC Recommendations |
57 |
Number of Negative CEDAC Recommendations |
61 |
Number of CEDAC Recommendations "Not Released" (Request for Advice) |
3 |
| |
Number of Priority Reviews Requested/Granted |
32/12 |
Number of PreNOC Pilot Submissions/Positively Recommended |
1 / 1
|
| |
Number of Unique Products Receiving Recommendations |
103 |
Number of Unique Products Receiving Positive Recommendations |
51 |
Number of Unique Products Receiving Negative Recommendations |
52 |
| |
The Newest CEDAC Recommendations from the Latest Update |
Volibris (Positive)
Xarelto (Positive)
Truvada (Positive, for Advice) |
The Newest CEDAC Recommendations from the Latest Update |
Olmetec / Olmetec Plus (for Hypertension)
|
CEDAC made two new recommendations on Nov 12, 2008: Celsentri and Omnaris
November 17, 2008:
HIV drug Celsentri (maraviroc) by Pfizer Canada Inc obtained CEDAC positive listing recommendation. It is for use in experienced adult patients.
Clinical improvement and cost similarity led to the positive final recommendation by CEDAC.
Celsentri costs $33 per day, which is more expensive than raltegravir (Isentress) ($27) for experienced patients, but cheaper than tipranavir/ritonavir ($39.74).
Omnaris is a ciclesonide nasal spray produced by Nycomed Canada Inc. indicated for Allergic Rhinitis (seasonal and perennial).
The negative recommendation is due to uncertainty of clinical advantage and being too costly compared to other existing nasal corticosteroids.
Omnaris costs $0.70 per day while other nasal corticosteroids cost about $0.31 - $0.49.
CDR Activity as of Nov 17, 2008 |
Number of CDR Submissions |
144 |
Number of CEDAC Recommendations |
120 |
| |
Number of Positive CEDAC Recommendations |
57 |
Number of Negative CEDAC Recommendations |
61 |
Number of CEDAC Recommendations "Not Released" (Request for Advice) |
2 |
| |
Number of Priority Reviews Requested/Granted |
32/12 |
Number of PreNOC Pilot Submissions |
1 |
| |
Number of Unique Products Received Recommendations |
101 |
Number of Unique Products Received Positive Recommendations |
48 |
Number of Unique Products Received Negative Recommendations |
53 |
| |
The Newest CEDAC Recommendations from the Latest Update |
Celsentri (Positive)
Omnaris (Negative) |
Access to New Medicines in Canada: A Look at CDR Reviewed Products
November 12, 2008:
Background
All new drugs (including New Chemical Entities (NCEs), new combination products and drugs with new indications) considered for benefit status in public drug plan formularies are subject to a standard review process, by the Common Drug Review (CDR)1 committee, a national body. All jurisdictions currently participate in the CDR process, with the exception of Québec.
CDR vs. Provincial Listings
Between September 2003 (the implementation of CDR) and September 2008, there are records of 110 submissions2 on 96 unique products that had completed the CDR process. More than half (53) of the products were listed by at least one CDR participating jurisdiction. The number of listed CDR reviewed products in each province is presented in Graph 1.
The CDR process does not replace the decision-making responsibility of provincial drug plans. If all publicly-funded drug plans were fully supportive of CDR, 100% agreement with CDR recommendations would be expected. However, based on the final CDR recommendation, it is up to each provincial drug plan to decide whether to list the drug product as a benefit in its own drug Formulary. Graph 2 presents the overall inconsistency rate among the four largest provinces. The inconsistency rate is defined as the share of provincial formulary listing decisions that are opposite of the CDR recommendations.
Currently, Ontario disagrees with 30% of all CDR recommendations (positive and negative). Ontario has not listed 27 drugs recommended by CDR and has listed 2 drugs not recommended by CDR. The 27% inconsistency rate in Alberta is solely due to not listing 26 drugs recommended by CDR. British Columbia disagrees with 29% of all CDR recommendations, as evidenced by 27 negative listing decisions following positive CDR recommendations and 2 positive listing decisions following negative CDR recommendations. Québec, which does not participate in the CDR, has not listed 12 drugs recommended by CDR and listed 15 drugs not recommended by CDR. The overall inconsistency rate in Québec is 28%.
Time to Listing
The “time to listing” for CDR reviewed drugs is calculated from the Health Canada application date (reflected by Central Registration (CR) Date) to reimbursement effective date under the respective drug plans. Graph 3 presents the time line for CDR reviewed drugs from obtaining Health Canada approval to reimbursement, in the 4 largest provinces respectively.
The average Health Canada approval time (CR date to NOC date) is almost 1.5 years (524 days) for new drugs approved over last 8 years. Preparation and review time varies from 1 year (in Québec) to 2 years (in British Columbia) depending on the province. In total, it took 3 to 4 years for CDR drugs to obtain market access under individual provincial drug plans.
It is also noted that manufacturers have been faster at preparing and submitting to CDR for process from the time that NOC is obtained (see Graph 4).
Conclusion
The national drug review body, CDR, has been in existence for 5 years. There are 96 unique products that had completed the CDR process. Provinces listing decisions are not bound by CDR recommendations. Participating provinces have listed half of the CDR reviewed drugs. In total, it took 3 to 4 years for new drugs to get market access (including Health Canada approval time).
______________
1Common Drug Review (CDR) was implemented by the Canadian Agency for Drugs and Technologies in Health (CADTH) on September 1, 2003.
2 There are 114 submissions on 98 unique products with inclusion of Request for Advice.
CEDAC made two positive recommendations on Oct 16, 2008: Humira and Stalevo
October 16, 2008:
Stalevo by Novartis, is a combination of levodopa, carbidopa & entacapone and is indicated for Parkinson’s disease. Stalevo achieved a similar treatment outcome to the individual components administered separately, but the fixed dose combination is less costly than the sum of components cost.
Humira is positively recommended for the 5th indication, psoriasis.
Significant achievement observed from the clinical trials plus lower cost than another psoriasis drug (Humira $18,191/year vs. Raptiva $21,420/year) lead to CEDAC’s positive final decision. (Note Raptiva also obtained positive recommendation on August 24, 2006).
Below is the provincial listing status for each of the Humira indications as of this date.
Humira Listing Status for Each of the Indications
Province |
Listing Status |
Humira Indications |
1 |
2 |
3 |
4 |
5 |
Rheumatoid Arthritis |
Psoriatic Arthritis |
Ankylosing Spondylitis |
Crohn’s disease |
Psoriasis |
AB |
SA |
yes |
yes |
yes |
yes |
|
BC |
SA |
yes |
yes |
yes |
yes |
|
MT |
SA |
yes |
yes |
|
yes |
|
NB |
SA |
yes |
yes |
yes |
yes |
|
NF&L |
SA |
yes |
yes |
yes |
yes |
|
NIHB |
LU |
yes |
|
|
|
|
NS |
E |
yes |
yes |
yes |
yes |
|
ON |
EAP |
|
|
|
|
|
PEI |
EDS |
yes |
|
|
yes |
|
QC |
EM |
yes |
yes |
yes |
yes |
|
SK |
EDS |
yes |
yes |
yes |
yes |
|
The order of indications are by submission time to CDR from oldest to newest.
Updated List of Medications
August 12, 2008: In 2009, the Minister of health and social Services authorised three updates to the Québec drug benefit list of the “Régime général d'assurance medicaments” and to the list of “médicaments-établissements.”
A notice was sent to drug manufacturers including a complete schedule for 2009 as well as other useful information. Read more
Competitive Agreement Ontario
July 11, 2008
On July 4, 2008, the OPDP announced their new initiative for “Competitive Agreements”, a follow-on to the features of Bill 102, The Transparent Drug System for Patients Act, that were directed at reducing reimbursed amounts for generic drugs under the OPDP. As we have reported elsewhere, the 50% generic price reduction contained in Bill 102 was a starting point in government efforts to capture a larger part of the potential generic savings.
Competitive agreements will be made with manufacturers of selected multi-source drugs who respond to Calls for Application. In principle, the molecules selected would have multiple generics available, have high volume with a high public share and have lower prices in other jurisdictions. (It is unclear whether this means in Canada or internationally). There are four molecules in the first wave with an unspecified number of molecules and waves to follow in the months to come. For each molecule, two winners will be named based on a combination of security of supply and lowest net price. Brand manufacturers are free to submit an Application.
The first four molecules along with the ODB reimbursements for 2007-08 are:
Enalapril maleate (Vasotec) $31.6 million*
Ranitidine hydrochloride (Zantac) $23.5 million
Metformin hydrochloride (Glucophage) $24.0 million
Gabapentin (Neurontin) $7.5 million
*generics available from Q4 2007, amount represents brand + generic reimbursements for Enalapril Maleate and Enalapril Sodium.
Price reductions will be implemented by a rebate paid quarterly direct to the government. The price listed in the formulary will be the normal generic price of 50% of the brand price. Maintaining the generic list price at 50% is sound policy making for the province since it removes a disincentive for generic manufacturers to compete. If the actual price were known, there would be pressure for this to become the price in other provinces. However, some provinces require manufacturers to provide them the lowest price at which their products are sold to retail.
If the brand manufacturer is one of the two winners, the brand price will be lowered to the generic price in the formulary. This may discourage brand manufacturers from competing for this business; this was understood by the OPDP but the regulations are such that this was unavoidable at this time. However, there are recent events which suggest brand companies are becoming more aggressive on pricing and more competitive versus generic manufacturers.
Security of supply constitutes 50% of the evaluation of the bid with bidders required to demonstrate experience in the Ontario marketplace and an ability to supply the entire OPDP requirement of the drug. In addition, a quantity of drug sufficient to supply three months total requirements of the OPDP shall be held as safety stock.
Price will be the other 50% of the evaluation. No volume guarantees are being made; rather the bidders have the ability to offer higher rebates at higher market shares using a four-tier structure. Detailed evaluation criteria are set out in the OPDP briefing available at:
http://www.health.gov.on.ca/english/providers/program/
drugs/opdp_eo/notices/stakeholder_briefing.pdf
Calls for Application will be issued on July 25, with a deadline of August 22. A decision will be made on September 12 and the contract will start by January 1, 2009 or earlier depending, partially, on ability to supply. Each molecule is a stand alone agreement; no “bundling” is permitted.
Only the successful applicants’ products will be listed in the formulary and be eligible for reimbursement; others will be listed as “not a benefit”. One exception is that should two generics be successful, the brand drug will be maintained in the formulary to allow for “no substitution” prescriptions at the prevailing brand price.
The contracts will run two years with the OPDP holding one-way option for an additional year. Interestingly, in New Zealand where tending has been used for several years, the winning company rarely tenders in subsequent years. This one-way option may be a very difficult hurdle for the risk-adverse company.
The OPDP has committed to openness and transparency in this regard and is holding a follow-up session on July 15th to hear concerns. In addition email comments are being received at competitiveagreements@ontario.ca. An Applicants’ conference is being held on August 1. It was mentioned that the initial wave was an opportunity to refine the process so that future waves would be trouble free. The openness of the process seems intended to gather as much input as possible to ensure success.
The naming of two winners of the Calls for Application is in keeping with the OPDP’s commitment that it would not implement “winner take all” agreements when the competitive agreement concept was first mentioned during the run-up to Bill 102’s proclamation. It remains to be seen if this feature will prompt the kind of competitive bidding among the generic firms that is sought and encourage brand manufacturers to participate as well.
To estimate the potential savings to the OPDP it is noted that the Saskatchewan Health Drug Plan currently reimburses Metformin and the most commonly used strength of Ranitidine at 30% and 25%, respectively, below the current OPDP cost on their Standing Offer Contract system. Given the larger OPDP expenditures, the relative savings could well be greater in Ontario if the manufacturers participate as intended. Based on the estimated current value of the four molecules savings on the order of those realized by Saskatchewan Health would net the OPDP about $20 million in savings over a year.
This initiative on the part of the OPDP is a continuation of the activities of public payers to reduce the cost of generic product to levels more in keeping with those seen in other countries and that was part of the National Pharmaceutical Strategy and that first materialized with Ontario Bill 102. The Ministry must be congratulated for its diligence in initiating new programs to contain costs and for the openness of this process. There will, inevitably, be unintended consequences and as with any other public policy, there will need to be close scrutiny of the results to evaluate the outcomes and adjust the process as subsequent waves are rolled out.
Tom Brogan
President
Brogan Inc. entered into an agreement with Rotman School of Management
Brogan Inc. and the University of Toronto’s Rotman School of Management have partnered to offer an innovative new training program: Customer-Focused Marketing for Pharma Professionals.
To learn more about this unique, industry specific marketing program visit:
http://ep.rotman.utoronto.ca/open/pharma_marketing/default.asp
Effect of Cost-Sharing on Use of Asthma Medication in Children
Brogan Inc. research staff in collaboration with researchers at the University of Toronto, utilizing Brogan Inc. Private Drug Plans database, have published the "Effect of Cost-Sharing on Use of Asthma Medication in Children" as the leading research article in the Archives of Pediatric and Adolescent Medicine, with an accompanying editorial. Read more »
Provincial Formulary Updates
Posted December 31, 2008
Alberta
Alberta Health and Wellness Drug Benefit List Quarterly Update Jan 2009
Highlights
Added Products: Apo-Valacyclovir 500MG Cap; Atacand 32MG Tab; Gen-Ramipril 1.25MG, 2.5MG, 5MG, 10MG Cap; Metrogel 1% Top Gel; PMS-Ibuprofen 400MG, 600MG Tab; PMS-Naproxen EC 375MG, 500MG Tab EC; PMS-Pantoprazole 40MG Tab EC; PMS-Rabeprazole EC 10MG, 20MG Tab EC; PMS-Topiramate 50MG Tab; Ran-Ramipril 1.25MG, 2.5MG, 5MG, 10MG Cap; Sandoz Clarithromycin 500MG Tab; Sandoz Rabeprazole 10MG, 20MG Tab EC; Stalevo 50MG/12.5MG/200MG, 100MG/25MG/200MG, 150MG/37.5MG/200 MG Tab. Discontinued Listings: Kenalog in Orabase 0.1% Dental Paste; PMS-Flavoxate 200MG Tab; Rhinalar 25MCG/DOSE Nasal Spray; Sandoz Risperidone 0.25MG Tab; Sibelium 5MG Cap; Symmetrel 100MG Cap; Viokase Oral Powder; Wellbutrin SR 100MG Tab SR; Westcort 0.2% Top Oint; Zyloprim 300MG Tab. Special Authorization: Apo-Cyclosporine, Neoral 100MG/ML Orl Sol; Ratio-Fentanyl, Duragesic 12 12MCG/HR Trans Pad.
Posted December 31, 2008
British Columbia
BC Pharmacare Newsletter 08-012, Dec 22, 2008
Highlights
Additions: Ratio Quetiapine 25mg, 100mg, 200mg, 300mg tab, Co Quetiapine 25mg, 100mg, 200mg, 300mg tab, Sandoz Quetiapine 25mg, 100mg, 200mg, 300mg tab, pms Quetiapine 25mg, 100mg, 200mg, 300mg tab, Gen Quetiapine 25mg, 100mg, 200mg, 300mg tab, Novo Quetiapine 25mg, 100mg, 200mg, 300mg tab, Apo Quetiapine 25mg, 100mg, 200mg, 300mg tab; Now Interchangeable: Seroquel 25mg, 100mg, 200mg, 300mg tab; Listed as Non Benefit: Novo Quetiapine 150mg tab.
Posted December 29, 2008
Nova Scotia
NS Pharmacare Vol #08-11, December 2008 Bulletin
Highlights
Discontinued: Nu-Cromolyn 1% Ampules; Zaditen 1mg/5ml Syr; Apo-Perindopril 8mg Tab. MAC Categories Removed from Reimbursement List: PMS-Sodium Cromoglycate 1% Neb Sol; Novo-Ketotifen 1mg/5ml Syr; Coversyl 8mg Tab. New Online Criteria Code: Midazolam 1mg/ml, 5mg/ml inj, generic brands. New Special MAC Category: Gliclazide 80mg Tabs. New Products: Emend 80mg, 125mg Cap, Tri-Pack Caps; Stalevo 50mg, 100mg, 150mg Tab; Suboxone 2mg/0.5mg, 8mg/2mg Sublingual Tab; Zeldox 20mg, 40mg, 60mg, 80mg Cap. Not Recommended: Cubicin 500mg Vial. Additional Criteria: Humira 40mg/0.8ml pen, 40mg/0.8ml Syringe Inj; Thyrogen 0.9mg/ml Inj. New Diabetic Products: Super-fine Pen Needles Standard 29g 12.7mm; Super-fine Pen Needles Micro 31g 5mm; Super-fine Needles Xtra 31g 8mm.
Posted December 29, 2008
New Brunswick
Benefit Changes to NBPDP, Bulletin #740 - December 23, 2008
Highlights
Additions: Advicor 1000mg & 40mg tab, Diovan 320mg tab, Biphentin 80mg cap; Revised Criteria: Plavix 75mg tab; Drugs Reviewed and Not Listed: Rasilez 150mg, 300mg tab, Adderall XR 5mg, 10mg, 15mg, 20mg, 25mg, 30mg cap, Aricept RDT 5mg, 10mg tab o/dis, Januvia 100mg tab, Ralivia 100mg, 200mg, 300mg tab, Aclasta 5mg/100ml vial.
Posted December 29, 2008
British Columbia
BC Pharmacare Newsletter, 08-013, December 22, 2008
Highlights
Status Clarification: Buprenorphine HCL 0.4mg, 2mg, 8mg tab; Additions: Apo Diltiaz TZ 120mg, 180mg, 240mg, 300mg, 360mg cap, Citalopram Odan 20mg, 40mg tab, Gen Ramipril 1.25mg, 2.5mg, 5mg 10mg cap, Mint Ondansetron 4mg, 8mg tab, Novo Morphine SR 60mg, 100mg, 200mg, Novo Clonidine 0.025mg tab, Ondansetron Odan 4mg, 8mg tab, Ondansetron Injection 2mg/ml (with preservative), 2mg/ml (without preservative), PMS ASA EC 650mg tab, pms Diclofenac 25mg, 50mg tab, pms Rabeprazole EC 10mg, 20mg tab, Ran Ramipril 2.5mg, 5mg, 10mg tab, Sandoz Paroxetine 20mg, 30mg tab, Sandoz Rabeprazole EC 10mg, 20mg tab, Sandoz Pramipexole 0.25mg, 0.5mg, 1mg, 1.5mg tab; Life Brand Portable Blood Glucose Strips; Added as a Non Benefit: Ciprofloxacin 2mg/ml iv sol; New LCA Categories: Apo Brimonidine 0.15% sol, Alphagan P 0.15% sol, Cefoxitin Inj 1g, 2g vial, Neoral 100mg/ml o/s, Apo Cyclosporine 100mg/ml o/s.
Posted December 19, 2008
New Brunswick
New Brunswick Formulary, Volume 50, Product Updates No 2, December 10, 2008
Highlights
New NBPDP Interchangeability Additions: pms Bupropion SR 150mg tab SR, Cefazolin 1g inj pws, Jamp Citalopram 20mg, 40mg tab, Odan Citalopram 20mg, 40mg tab, Sandoz Diclofenac 50mg, 100mg supp, Apo Diltiazem TX 120mg, 180mg, 240mg, 300mg, 360mg cap ER, Co Etidrocal 400mg & 500mg tab, Didrocal 400mg & 500mg tab, Co Famciclovir 125mg, 250mg, 500mg tab, pms Gabapentin 600mg, 800mg tab, Gen Leflunomide 10mg, 20mg tab, Mint Ondansetron 4mg, 8mg tab, Odan Ondansetron 4mg, 8mg tab, Sandoz Paroxetine 20mg, 30mg tab, Sandoz Pamipexole 0.25mg, 0.5mg, 1mg, 1.5mg tab, Apo Quetiapine 25mg, 100mg, 200mg, 300mg tab, Sandoz Quetiapine 25mg, 100mg, 200mg, 300mg tab, Novo Quetiapine 150mg tab, Seroquel (DISC) 150mg tab, pms Rabeprazole EC 10mg, 20mg tab ent, Apo Ranitidine 150mg, 300mg tab, Erdol 8288U/ml drops, Disdol 8288U/ml drops, Xatral 10mg tab ER, Apo Alfuzosin 10mg tab ER, Cefazolin 10g inj pws, Sandoz Paroxetine 10mg tab, Pipercillin & Tazobactam 2g & 0.25g, 3g & 0.375g, 4g & 0.5g inj pws, Tazocin 2g & 0.25g, 3g & 0.375g, 4g & 0.5g inj pws, Apo Ranitidine 75mg tab.
Posted December 19, 2008
New Brunswick
Benefit Changes to NBPDP, Bulletin #738, December 10, 2008
Highlights
NBPDP Benefit Additions: pms Bupropion SR 150mg tab SR, Cefazolin 1g inj pws, Jamp Citalopram 20mg, 40mg tab, Odan Citalopram 20mg, 40mg tab, Sandoz Diclofenac 50mg, 100mg supp, Apo Diltiazem TX 120mg, 180mg, 240mg, 300mg, 360mg cap ER, Co Etidrocal 400mg & 500mg tab, Co Famciclovir 125mg, 250mg, 500mg tab, pms Gabapentin 600mg, 800mg tab, Gen Leflunomide 10mg, 20mg tab, Mint Ondansetron 4mg, 8mg tab, Odan Ondansetron 4mg, 8mg tab, Sandoz Paroxetine 20mg, 30mg tab, Sandoz Pamipexole 0.25mg, 0.5mg, 1mg, 1.5mg tab, Apo Quetiapine 25mg, 100mg, 200mg, 300mg tab, Sandoz Quetiapine 25mg, 100mg, 200mg, 300mg tab, Novo Quetiapine 150mg tab, pms Rabeprazole EC 10mg, 20mg tab ent, Apo Ranitidine 150mg, 300mg tab, Erdol 8288U/ml drops, Apo Alfuzosin 10mg tab ER, Cefazolin 10g inj pws, Sandoz Paroxetine 10mg tab, Pipercillin & Tazobactam 2g & 0.25g, 3g & 0.375g, 4g & 0.5g inj pws, Apo Ranitidine 75mg tab.
Posted December 17, 2008
Quebec
Correction No 5 to the Liste de medicaments effective Dec 17, 2008.
Highlights
Modifications: Pipercillin & Tazobactam 2g & 0.25g, 3g & 0.375g, 4g & 0.5g iv pws, Apo Feno Super 160mg tab, Lipidil Supra 160mg tab, Novo Fenofibrate S 160mg tab, Gen Lisinopril HCTZ 20mg & 12.5mg tab, Novo Lisinopril HCTZ (Type Z) 20mg & 12.5mg tab, Sandoz Lisinopril HCT 20mg & 12.5mg tab, Zestoretic 20mg & 12.5mg tab, Novo Difenac 25mg tab ent, Novo Difenac SR 75mg tab, Modecate Concentre 100mg/ml inj sol, Apo Quetiapine 200mg tab, Co Quetiapine 200mg tab, Gen Quetiapine 200mg tab, Novo Quetiapine 200mg tab, pms Quetiapine 200mg tab, Ratio Quetiapine 200mg tab, Riva Quetiapine 200mg tab, Apo Quetiapine 300mg tab, Co Quetiapine 300mg tab, Novo Quetiapine 300mg tab, pms Quetiapine 300mg tab, Ratio Quetiapine 300mg tab, Riva Quetiapine 300mg tab, Contour Test Strips, Pro Cal D 400 500mg & 400mg tab, Rhinaris CS 2% nas aem, Euthyrox 0.025mg tab, Euthyrox 0.05mg tab, Euthyrox 0.075mg tab, Euthyrox 0.088mg tab, Euthyrox 0.1mg tab, Euthyrox 0.112mg tab, Euthyrox 0.125mg tab, Euthyrox 0.137mg tab, Euthyrox 0.15mg tab, Euthyrox 0.175mg tab, Euthyrox 0.2,g tab, Euthyrox 0.3mg tab
Posted December 17, 2008
Ontario
ODB Update E, No.41. Effective December 23, 2008
Highlights
New Multi-Source Drugs: Co Famciclovir 500mg Tab; Mint-Ondansetron 4mg, 8mg Tab; Novo-5-ASA 400mg Tab; PMS-Bupropion SR 150mg Tab; Ran-Ondansetron 4mg, 8mg Tab. New Drug Identification Numbers: Monistat Derm 2% Cr; Percocet 5mg, 325mg Tab; Percodan 5mg, 325mg Tab. Manufacturer Requested Discontinued Drugs: Monostat Derm 2% Cr; Percocet 5mg, 325mg Tab; Percodan 5mg, 325mg Tab; Surgam 300mg Tab; Vitamin A Acid 0.05% Cr. Drug Benefit Prices: Apo-Quetiapine 200mg, 300mg Tab; Fenomax 160mg Tab; Flovent HFA 50mcg INH; Fraxiparine 9500IU/ml; Fraxiparine Forte 19000IU/ml; Novo-Difenac 25mg Tab Ent; Telzir 700mg Tab. New Manufacturer Names: Boost 1.0 Standard; Boost 1.5 Plus Calories; Boost Fruit Flavored Beverage; Compleat Modified; Compleat Paediatric; IsoSource 1.5 Cal, HN, HN with Fibre, VHN; MCT oil; NovaSource Renal; Resource 2.0; Resource Diabetic; Resource Just for Kids 1.5 Cal; Tolerex; Vivonex Pediatric, Plus, T.E.N. Off Formulary Interchangeable Products: Co Famciclovir 125mg, 250mg Tab; PMS-Cetirizine 20mg Tab; PMS-Pantoprazole 20mg Tab ENT; Ratio-Fentanyl 12mcg/hr Trans Patch; Ratio-Tecnal C1/4 300mg, 50mg, 40mg, 15mg Cap; Ratio-Tecnal ½ 330mg, 50mg, 40mg, 30mg Cap; Ratio-Tecnal 330mg, 50mg, 40mg Cap; Sandoz Lisinopril HCT 20mg, 25mg Tab. Limited Use Changes: Xeloda 150mg, 500mg Tab. Trade Name Changes: Breeze 2 Strip; Coversyl Plus LD. New Diabetic Testing Agent: Nova Max Strip.
Posted December 17, 2008
Ontario
ODB Update E1, No.41. Effective January 8, 2009
Highlights
Drug Benefit Prices: Vasotec 2.5mg, 5mg, 10mg, 20mg tab; Not A Benefit Drugs: Apo Enalapril 2.5mg, 5mg, 10mg, 20mg, Co Enalapril 2.5mg, 5mg, 10mg, 20mg, Gen Enalapril 2.5mg, 5mg, 10mg, 20mg, Novo Enalapril 2.5mg, 5mg, 10mg, 20mg, PMS Enalapril 2.5mg, 5mg, 10mg, 20mg, Ratio Enalapril 2.5mg, 5mg, 10mg, 20mg, Sandoz Enalapril 2.5mg, 5mg, 10mg, 20mg, Taro Enalapril 2.5mg, 5mg, 10mg, 20mg.
Posted December 12, 2008
Newfoundland
Newfoundland and Labrador Prescription Drug Program Bulletin No. 49
Highlights
Additions to the Interchangeable Drug Products Formulary: Co Lisinopril 5mg, 10mg, 20mg tab, Gen Lisinopril 5mg, 10mg, 20mg tab, pms Lisinopril 5mg, 10mg, 20mg tab, Sandoz Lisinopril 5mg, 10mg, 20mg tab, Co Sotalol 80mg, 160mg tab
Posted December 12, 2008
Newfoundland
Newfoundland and Labrador Prescription Drug Program Bulletin No. 48
Highlights
Additions: Co Lisinopril 5mg, 10mg, 20mg tab, Gen Lisinopril 5mg, 10mg, 20mg tab, pms Lisinopril 5mg, 10mg, 20mg tab, Sandoz Lisinopril 5mg, 10mg, 20mg tab, Co Sotalol 80mg, 160mg tab.
Posted December 12, 2008
Newfoundland
Bulletin #46 - 2008 12 09
Highlights
Delisted: Apo-Ampi 125mg/5ml Oral Liquid; Novo-Ampicillin 125mg/5ml Oral Liquid; Nu-Ampi 250mg Cap; Endo-Levodopa/Carbnidopa 10/100mg Tab; pms-Cephalexin 250mg Tab; Novo-Cholamine Light Sachets; Novo-Dipiradol 75mg Tab; ratio-Nadolol 160mg Tab; Naxen 375mg Tab; Naxen 500mg Tab; Synflex DS 550mg tab; ratio-Nortriptyline 25mg Cap; pma-Piroxicam 20mg Cap; Novo-Pranol 120mg Tab.
Posted December 10, 2008
Alberta
Additions to the AHWDBL - December 1, 2008
Highlights
Additions to the AHWDBL: Apo Quetiapine 100mg, 200mg, 300mg tab, Co Quetiapine 100mg, 200mg, 300mg tab, Novo Quetiapine 100mg, 200mg, 300mg tab, pms Quetiapine 100mg, 200mg, 300mg tab, Gen Quetiapine 100mg, 200mg, 300mg tab, Ratio Quetiapine 100mg, 200mg, 300mg tab, Sandoz Quetiapine 100mg, 200mg, 300mg tab, Seroquel 100mg, 200mg, 300mg tab.
Posted December 5, 2008
Prince Edward Island
December 2008 Update to the Maximum Allowable Cost List
Highlights
Products Added to the Interchangeable/MAC List: Octreotide Acetate 200UG/ML Inj; Ran-Ondansetron 4MG, 8MG Tab; Ran-Ramipril 1.25MG, 2.5MG, 5MG, 10MG Tab. Changes to MAC Prices: Pravastatin 10MG, 20MG, 40MG Tab; Ramipril 1.25MG, 2.5MG, 5MG, 10MG Cap. Discontinued Products: Surgam 300MG Tab.
Posted December 5, 2008
Quebec
Correction No 4 to the Liste de Medicaments - November 24, 2008
Highlights
Additions: pms Sulfasalazine 500mg tab, pms Sulfasalazine EC 500mg tab, Fenomax 160mg tab, Apo Feno Super 160mg tab, Novo Fenofibrate-S 160mg tab, Pro Feno Super-160 160mg tab, Sandoz Fenofibrate S 160mg tab, Apo Diclo 25mg tab ENT, Diclofenac-25 25mg tab ENT, pms Diclofenac 25mg tab ENT, Sandoz Diclofenac 25mg tab ENT, Apo Diclo SR 75mg tab SR, Diclofenac-SR 75mg tab SR, pms Diclofenac-SR 75mg tab SR, Sandoz Diclofenac SR 75mg tab SR
Posted December 5, 2008
Quebec
Modification No 2 to the Liste de Medicaments - November 21, 2008
Highlights
Change in Criteria: Anzemet, Kytril, Zofran, Zofran ODT, generic Ondansetron products; Additions: Emend 125mg cap, Emend TriPack 125mg, 80mg cap, Apo Quetiapine 25mg, 100mg, 200mg, 300mg tab, Co Quetiapine 25mg, 100mg, 200mg, 300mg tab, Gen Quetiapine 25mg, 100mg, 200mg, 300mg tab, Novo Quetiapine 25mg, 100mg, 200mg, 300mg tab, pms Quetiapine 25mg, 100mg, 200mg, 300mg tab, Riva Quetiapine 25mg, 100mg, 200mg, 300mg tab, Sandoz Quetiapine 25mg, 100mg, 200mg, 300mg tab, Nutren 1.5 o/l; Modifications: Ratio Quetiapine 200mg, 300mg tab, pms Desonide 0.05% top sol, pms Acetaminophen 500mg tab, Gen Tamsulosin 0.4mg tab ER, Novo Tamsulosin 0.4mg tab ER, Ran Tamsulosin 0.4mg tab ER, Ratio Tamsulosin 0.4mg tab ER, Sandoz Tamsulosin 0.4mg tab ER, Zanaflex 4mg tab; Discontinued by Manufacturer: Nutren 1.5 o/l; Refused due to economic and pharmacoeconomic reasons: Nexavar 200mg tab.
Posted November 28, 2008
New Brunswick
Benefit changes to NBPDP, Bulletin # 737, Nov 26, 2008
Highlights
Regular Benefit Additions: Aranesp 200mcg IV SOL. Special Authorization Additions: Campral 333mg Tab; Atripla 200mg, 300mg, 600mg Tab; Prevacid FasTab 15mg Tab; Isentress 400mg Tab. Special Authorization – Revised Criteria: Fosamax and Generics 10mg, 70mg Tab; Actonel 5mg, 35mg Tab; Miacalcin 200IU Nasal Spray; Evista 60mg Tab. Drugs Reviewed and Not Listed: Lipidil EZ 48mg, 145mg Tab; Invega 3mg, 6mg, 9mg Tab ER; Tridural 100mg, 200mg, 300mg Tab.
Posted November 28, 2008
Quebec
Quebec Capsule - Avis Special - Nov 26, 2008
Highlights
Additions to Liste de Medicaments: Emend 80MG, 125MG CAP. Declined due to economic and pharmoeconomic reasons: Nexavar 200MG TAB. Criteria Change: Anzemet 50MG, 100MG TAB; Kytril 1MG TAB; Zofran 4MG, 8MG TAB, 0.8MG/ML O/L; Zofran ODT 4MG, 8MG TAB.
Posted November 26, 2008
Ontario
ODB update D, Effective Dec 3, 2008
Highlights
Additions: Enbrel 50mg/ml Inj Pref Syr, Lantus 100u/ml inj sol, Raptiva 150mg inj pd, Rasilez 150mg, 300mg tab, Apo Quetiapine 25mg, 100mg, 200mg, 300mg tab, Co Quetiapine 25mg, 100mg, 200mg, 300mg tab, Gen Quetiapine 25mg, 100mg, 200mg, 300mg tab, Novo Quetiapine 25mg, 100mg, 200mg, 300mg tab, pms Quetiapine 25mg, 100mg, 200mg, 300mg tab, Sandoz Quetiapine 25mg, 100mg, 200mg, 300mg tab, Sandoz Cefprozil 125mg/5ml, 250mg/5ml o/l, Sandoz Omeprazole 20mg cap, Orencia 250mg/vial; Discontinued by Manufacturer: pms Diclofenac 25mg, 50mg tab ent, Sibelium 5mg cap; Price Change: Apo Alfuzosin 10mg tab, Nexavar 200mg tab; Off Formulary Interchangeable Products: Apo Feno Super 100mg tab, Novo Cyproterone/Ethinyl Estradiol 2mg & 0.035mg tab, Novo Quetiapine 150mg, Pipercillin & Tazobactam for Injection 2g & 250mg, 3g & 375mg, 4g & 500mg inj pd, Ratio Tryptophan 500mg cap, 500mg tab, 1g tab, Taro-Warfarin 6mg tab; New Nutrition Products: Jevity 1.5 Cal o/l.
Posted November 21, 2008
Nova Scotia
Nova Scotia Pharmacare Bulletin #08-10
Highlights
PIN Correction: Pouchkins Pediatric; Products no longer considered a special MAC: Diamicron MR 30mg tab; New Interchangeable Products Added to the Nova Scotia Formulary: 99 - please see bulletin for full list; New Products - Not Interchangeable: Erdol 8.288U/ml sol, Magnesium Odan 5mg/ml o/l; New Non Insured Products: Sandoz Clarithromycin 250mg, 500mg tab.
Posted November 19, 2008
British Columbia
BC Pharmacare Newsletter Edition 08-011
Highlights
Discontinued PINs: Infusion sets/kits and Infusion Syringes; Additions Insulin Pumps: Animas 2020, Deltec Cozmo, Paradigm 522, Paradigm 722; Additions Insulin Pump Supplies: Cozmo 3ML IP Cartridge, Thinset 1.8ML or 3ML IP Reservoir, Thinset 3ML IP Syringe Reservoir, Animas 2ML or 3ML Cartridge, Accu-chek Spirit 3.15ML IP Cartridge, Mininmed 3cc IP Syringe Reservoir, Paradigm 1.76ML or 3ML IP Cartridge, Cleo 90 Infusion Set, Comfort Cannulas, Comfort Infusion Set/Combo/Short Combo, Contact Detach Infusion Set, Thalaset Infusion Set, Thinset Infusion Set, Comfort Infusion Set or Combo, Contact Detach Infusion Set, Inset II or 30 Infusion Set, Accu-chek Rapid D Infusion Set, Accu-chek Tender 1 or 2 Infusion Set, Accu-chek Ultraflex 1 or 2 Infusion Set, Paradigm Polyfin QR Infusion Set, Paradigm Quickset Infusion Set, Paradigm Silhouette Infusion Set/Combo, Paradigm Sofset QR Infusion Set, Paradigm Sure-T Infusion Set, Minimed Polyfin or Polyfin QR Infusion Set, Minimed Quickset Infusion Set, Minimed Silhouette Infusion Set or Combo, Minimed Sofset or Sofset QR Infusion Set.
Posted November 17, 2008
New Brunswick
Bulletin #734 - November 12, 2008
Highlights
Oseltamivir (Tamiflu) for NBPDP Beneficiaries in Long-term Care Facilities - Information for Pharmacies Providing Services to Licensed Nursing Homes
Posted November 14, 2008
Prince Edward Island
November 2008 Update to the Maximum Allowable Cost List
Highlights
Products Added to the Interchangeable List: Mint Topiramate 25mg, 100mg, 200mg tab, pms Diclofenac 25mg, 50mg tab ent, Sandoz Diclofenac 50mg, 100mg supp; Changes to MAC Prices: Symmetrel 100mg cap, pms Amantadine 100mg cap, Endantadine 100mg cap, Gen Amantadine 100mg cap, Diamicron MR 30mg tab ER, Apo Gliclazide MR 30mg tab ER; Deleted Interchangeable MAC Categories: Clavulin 250mg & 125mg tab, Apo Amoxi Clav 250mg & 125mg tab, Ratio Aclavulanate 250mg & 125mg tab, Cytoxan 25mg tab, Procytox 25mg tab, Sibelium 5mg cap, Apo Flunarizine 5mg cap; Discontinued Products: pms Diclofenac 25mg, 50mg tab ent, Sandoz Diclofenac 50mg, 100mg supp, Symmetrel 100mg cap, Wellbutrin SR 100mg tab SR.
Posted November 13, 2008
Quebec
Correction No 3 to the Liste de medicaments, effective Nov 12, 2008
Highlights
Additions: Sandoz Diclofenac 50MG, 100MG; Jamp-Citalopram 20MG, 40MG; Calcite D 500MG; Riva-D 400U. Price Modifications: Orfenace 100MG; Apo-Diclo SR 75MG, 100MG; Breeze 2 Disque (10); Dairy-Free 3000U; Jamp-Enzyme Lactase 3000U; Dairy-Free Extra Strength 4500U; Jamp-Enzyme Lactase Ex Str 4500U; Co Ranitidine 150MG, 300MG.
Posted November 12, 2008
Newfoundland
Behind the Scenes - Newfoundland and Labrador Prescription Drug Program (NLPDP) Fall 2008
Highlights
New Open Benefits: Pariet, Novo Rabeprazole, Ran Rabeprazole, Losec, Apo Omeprazole, Ratio Omeprazole, Sandoz Omeprazole, Lamictal, Apo Lamotrigine, Gen Lamotrigine, Novo Lamotrigine, pms Lamotrigine, Ratio Lamotrigine, Atacand, Atacand Plus, Avapro, Avalide, Cozaar, Hyzaar, Diovan, Diovan HCT, Micardis, Micardis Plus, Teveten, Teveten Plus, pms hydrochlorthiazide, pms amiodarone, Citalopram, Mezavant, Resultz; Special Authorization Additions/Updates: Pegasys, Baraclude, Hepsera, Emend, Eprex; New Coverage Criteria: Alendronate, Actonel, Evista, Calcitonin Nasal Spray, Remicade, Enbrel, Raptiva, Sprycel; Not Recommended by CDR: Thelin, Adderall, Januvia, Ralivia, Tridural, Spirafil, Fosrenal, Aclasta, Rasilez, Sativex; Not Recommended by ACDR: Remicade, Hymatrope for Idopathic Short Stature.
Posted November 12, 2008
Newfoundland
Bulletin No. 42 - October 29, 2008
Highlights
Updated Criteria for Long Acting Bronchodilators in COPD effective November 1, 2008: Spiriva 18mcg inh cap, Foradil 12mcg inh cap, Oxeze 12mcg, 6mcg inh pd, Serevent 25mcg inh aem, 50mcg inh pd, 25mcg inh aem, 50mcg inh pd, Serevent Diskhaler 50mcg inh pd, Advair 25mcg & 125mcg, 25mcg & 250mcg inh aem, Advair Diskus 50mcg & 100mcg, 50mcg & 250mcg, 50mcg & 500mcg inh pd, Symbicort 100mcg & 6mcg, 200mcg & 6mcg inh pd.
Posted November 12, 2008
British Columbia
BC Pharmacare Newsletter, Edition 08-010, effective Nov 7, 2008
Highlights
New PINs for: Methadone, Buprenorphine HCL; New Drugs Categorized to LCA: Apo Gabapentin 600mg, 800mg tab, Gen Venlafaxine 37.5mg, 75mg, 150mg tab, Ramipril 1.25mg, 2.5mg, 5mg, 10mg cap, Sandoz Clarithromycin 250mg, 500mg tab, Sandoz Risperidone 0.25mg, 0.5mg tab; New LCA Categories: Duragesic 12mcg trans pad, Ratio Fentanyl 12mcg trans pad, Apo Pantoprazole 40mg tab, Co Pantoprazole 40mg tab, Gen Pantoprazole 40mg tab, Novo Pantoprazole 40mg tab, Pantoloc 40mg tab, pms Pantoprazole 40mg tab, Ran Pantoprazole 40mg tab, Ratio Pantoprazole 40mg tab, Sandoz Pantoprazole 40mg tab, Apo Valacyclovir 500mg tab, pms Valacyclovir 500mg tab, Valtrex 500mg tab; Additions: Gen Clozapine 50mg, 200mg tab; Added as Non Benefit: Apo Pantoprazole 20mg tab, Novo Pantoprazole 20mg tab, Ran Pantoprazole 20mg tab, Ratio Pantoprazole 20mg tab, Sandoz Pantoprazole 20mg tab.
Posted November 3, 2008
Quebec
Modification No 1 et Correction No 2 a la liste de medicaments - 22 edition in effect Oct 29, 2008
Highlights
Additions: Piperacillin/Tazobactam Injection 2g & 0.25g inj pws, Pro Fluconazole 100mg, 150mg cap, Pro Lisinopril-5 5mg tab, Pro Lisinopril-10 10mg tab, Pro Lisinopril-20 20mg tab, ratio Quetiapine 20mg, 100mg, 200mg, 300mg tab; Modifications: 42 – see bulletin for details.
Posted November 3, 2008
Nova Scotia
Pharmacare Bulletin Vol #08-09, October 2008
Highlights
Exception Status Criteria of New Benefit: Cymbalta 30mg, 60mg Cap. Non-Insured Products: Aclasta 5ml/100ml Inj; Exelon Patch 4.6mg/24hr, 9.5mg/24hr; Intelence 100mg Tab; Isentress 400mg Tab; Januvia 100mg Tab; Ralivia 100mg, 200mg, 300mg Tab; Rasilez 150mg, 300mg Tab. New Ostomy Product: Pouchkins Pediatric. Insured as a full benefit under the Drug Assistance for Cancer Patients: Gabapentin (all strengths).
Posted November 3, 2008
Alberta
Additions to the AHWDBL, effective Nov 1, 2008
Highlights
New Drug Products Added to the AHWDBL: pms Quetiapine 25mg tab, Apo Quetiapine 25mg, 100mg, 200mg, 300mg tab, Co Quetiapine 25mg, 100mg, 200mg, 300mg tab, Gen Quetiapine 25mg, 100mg, 200mg, 300mg tab, Novo Quetiapine 25mg, 100mg, 200mg, 300mg tab, Ratio Quetiapine 25mg, 100mg, 200mg, 300mg tab, Sandoz Quetiapine 25mg, 100mg, 200mg, 300mg tab, Gliclazide 30mg tab SR; Now Interchangeable: Seroquel 25mg, 100mg, 200mg, 300mg tab.
Posted October 27, 2008
Ontario
Edition 41, Update C, effective Nov 4, 2008
Highlights
New Single Source Drugs: Cipralex 10mg, 20mg Tabs; Hyzaar 100mg & 12.5mg Tab; Somatuline Autogel 60mg/0.3mL, 90mg/0.3mL, 120mg/0.5mL ER Pref Syr. New Multi-Source Drugs: Apo-Alfuzosin 10mg Prolong-Rel Tab; Fenomax 160mg Tab; Ran-Ramipril 1.25mg, 2.5mg, 5mg & 10mg Caps; Ratio-Quetiapine 25mg, 100mg, 200mg & 300mg Tabs; Sandoz Alfuzosin 10mg Prolong-Rel Tab; Sandoz Pramipexole 0.25mg, 1mg & 1.5mg Tabs. Exceptional Access Products: Aclasta 5mg/100mL Inj Sol; Posanol 40mg/mL O/L. Drug Benefit Prices: 60 Price Change, see complete bulletin for details. Palliative Care Drugs: Aredia 3mg/mL & 9mg/mL Inj Sol; Pamidronate Disodium 3mg/mL, 6mg/mL & 9mg/mL Inj Sol; PMS-Pamidronate 3mg/mL & 9mg/mL Inj Sol. Status Change from Limited Use to Off Formulary Interchangeable Product: Apo-Brimonidine P 0.15% Oph Sol. Off Formulary Interchangeable Products: Novamoxin Chewable 125mg & 250mg Tabs; Novo-Fenofibrate Micronized 67mg Cap; Novo-Fenofibrate-S 100mg Tab; Novo-Ketorolac 10mg Tab; Novo-Ketotifen 1mg Tab; Novo-Minocycline 50mg & 100mg Caps; Novo-Naprox 250mg, 375mg & 500mg Ent Tabs; Ran-Pantoprazole 20mg Ent Tab; Sandoz Pantoprazole 20mg Ent Tab.
Posted October 15, 2008
Quebec
Correction #1 - Liste Des Medicaments Effective October 1, 2008
Highlights
Removed from the Formulary: Simlac PM o/l
Posted October 6, 2008
New Brunswick
New Brunswick Formulary, September 2008
Highlights
Full Formulary Release
Posted October 1, 2008
Alberta
Quarterly Updates and DBL report, October 1, 2008
Highlights
Highlights to follow shortly.
Posted October 1, 2008
Saskatchewan
Saskatchewan Bulletin # 116, October 1, 2008
Highlights
New Full Formulary Listings: NovaMax test strip; On-Call Plus test strip; Metrogel-GAC 1% top gel; Diovan-HCT-NVR 320mg/12.5mg, 320mg/25mg tab. New Exception Drug Status Listings: Atripla – BMY 600mg/200mg/300mg tab; Isentress-MSD 400mg tab; Advagraf-APC 0.5mg, 50mg, 200mg tab; Ratio-Pantoprazole-RPH, Sandoz Pantoprazole-SDZ 20mg Tab ENT. Revised Exception Drug Status Criteria: Raptiva-SRO PWS 150mg/vial; Enbrel-AMG 25mg/vial pre-filled syringe; Remicade-SCH 100mg/vial Injection; Symbicort Turbuhaler-AST 6ug/100ug, 6ug/200ug INH PD; Advair-GSK 25ug/125ug, 25ug/250ug Metered dose inhaler; Advair Diskus-GSK 50ug/100ug, 50ug/250ug, 50ug/500ug INH PD. Drugs Currently Under Review by the Sask. Review Committees: Cymbalta, Intellence, Januvia, Lucentis, Zeldox. New Interchangeable Listing Effective June 1, 2008: pms-Valacyclovir 500mg tab. New Interchangeable Listings Effective July 1, 2008: Citalopram Odan-ODN 20mg, 40mg Tab; Sandoz Paroxetine-SDZ 10mg, 20mg, 30mg Tab; Apo-Valacyclovir-APX 500mg Tab; Gen-Venlafaxine XR-GPM, Sandoz Venlafaxine XR-SDZ 37.5mg, 75mg, 150mg Cap. New Interchangeable EDS Listings Effective July 1, 2008 According to Current EDS Criteria: Sandoz Clarithromycin-SDZ 250mg Tab; Novo-Clonidine-NOP 0.025mg Tab; Co Pantoprazole-COB, Gen-Pantoprazole-GPM, Pms-Pantoprazole-PMS, Ratio-Pantoprazole-RPH, Sandoz Pantoprazole-SCZ 40mg Tab; Pms-Rabeprazole EC-PMS 10mg, 20mg Tab. New Interchangeable EDS Listing Effective July 28, 2008 According to Current Criteria: Ratio-Fentanyl-RPH 12ug/hr. New Interchangeable Full Formulary Listings Effective September 1, 2008: Apo-Brimonidine P-APX 0.15% OPH SOL; Pms-Diclofenac-PMS 25mg, 50mg Tab; Pms-Ibuprofen-PMS 400mg, 600mg Tab; Sandoz Pramipexole-SDZ 0.25mg, 0.5mg, 1mg, 1.5mg Tab; Gen-Ramipril-GPM 1.25mg, 2.5mg, 5mg, 10mg Cap. New Interchangeable EDS Listings Effective September 1, 2008 According to Current EDS Criteria: Sandoz Rabeprazole-SDZ 10mg, 20mg Tab. Drugs Reviewed and Not Recommended: Dovobet-LEO 50ug/0.5mg/G Oint; Rasilez-NVR 150mg, 300mg Tab; Invega-JAN 3mg, 6mg, 9mg Tab ER, Exelon 5 Exelon 10-NVR 4.6mg/24hr; 9.5mg/24hr Trans Pad; Tridural-PAL, Ralivia-BVL 100mg, 200mg, 300mg Tab ER; Aclasta-NVR 5mg/100ml Inj Sol. Reactivated DINs July 1, 2008: Ascensia Microlet Lancet; Voltaren SR 100mg SR Tab. Effective October 1, 2008 the following products will be listed as benefits: Apo-Afluzosin 10mg XR Tab; Pms-Bupropion SR 150mg Tab SR; Apo-Diltiazem TZ 120mg, 180mg, 240mg, 300mg, 360mg Cap ER; Dopred (reactivated DIN) 1% oph Susp; Apo-Quetiapine 25mg, 100mg, 200mg, 300mg Tab; CO Quetiapine 25mg, 100mg, 200mg, 300mg Tab; Gen-Quetiapine 25mg, 100mg, 200mg, 300mg; Novo-Quetiapine 25mg, 100mg, 200mg, 300mg Tab; Pms-Quetiapine 25mg, 100mg, 200mg, 300mg Tab; Ratio-Quetiapine 25mg, 100mg, 200mg, 300mg Tab; Sandoz Quetiapine 25mg, 100mg, 200mg, 300mg Tab. Additional Insulin Pump Supplies October 1, 2008: Inset 30 Infusion set.
Posted October 1, 2008
Quebec
Quebec Capsule, October 1, 2008
Highlights
Additions: Intelence 100mg tab, Januvia 100mg tab, Rasilez 150mg, 300mg tab, Seasonale 0.03mg & 0.15mg tab, Stalevo 50mg & 12.5mg, 200mg tab, 100mg & 25mg & 200mg tab, 150mg & 37.5mg & 200mg tab, Tysabri 300mg/15ml iv sol, Volbris 5mg, 10mg tab; Change in Criteria: Aclasta 5mg/100ml iv sol, Aricept 5mg, 10mg tab, Aricept RDT 5mg, 10mg tab o/dis, Excelon 1.5mg, 3mg, 4.5mg 6mg tab, Excelon Patch 9mg, 18mg trans pad, Reminyl ER 8mg, 16mg, 24mg cap ER, Hepsera 10mg tab; Refused due to Therapeutic Value: Activelle 1mg & 0.5mg tab, Activelle LD 0.5mg & 1mg tab, Cymbalta 30mg, 60mg cap ER, Omnaris 50mcg nas aem, Revlimid 5mg, 10mg cap, Vectibix 20mg/ml iv sol; Refused due to Economic and Pharmacoeconomic Value: Faslodex 50mg/ml inj sol, Torisel 25mg/ml inj sol.
Posted September 24, 2008
Ontario
ODB update B, effective October 1, 2008
Highlights
New Multi Source Drug(s): Apo-Brimonidine P 0.15% oph sol, Citalopram-Odan 20mg, 40mg tab, Novo-Oxycodone Acet 5mg & 325mg tab, Sandoz Rabeprazole 10mg, 20mg tab, Ondansetron-Odan 4mg, 8mg tab, PMS Diclofenac 25mg, 50mg tab ent, Sandoz Paroxetine 20mg, 30mg tab; Discontinued by Manufacturer: C.E.S 1.25mg tab, Cardizem 60mg tab, M.O.S 5mg/ml o/l, Sandoz Paroxetine 20mg, 30mg tab, Terazol 3 80mg vag supp, Vitamin B6 25mg tab; Price Changes: Diamicron MR 30mg tab SR, Kaletra 80mg/ml & 20mg/ml o/l, Kaletra 200mg & 50mg tab, Zantac 150mg, 300mg tab; Off Formulary Interchangeable Products: Apo-Ketorolac 10mg tab, Supeudol 20mg tab.
Posted September 22, 2008
New Brunswick
New Brunswick Formulary, Volume 50 - Update 1, September 18, 2008
Highlights
Additions to the Interchangeable Pharmaceutical Products List: Alphagan P 0.15% oph sol, Apo-Brimonidine 0.15% oph sol, Fiorinal 50mg & 330mg & 40mg cap, ratio-Tecnal 50mg & 330mg & 40mg cap, Fiorinal C1/4 50mg & 330mg & 40mg & 15mg cap, ratio-Tecnal C1/4 50mg & 330mg & 40mg & 15mg cap, Fiorinal C1/2 50mg & 330mg & 40mg & 30mg cap, ratio-Tecnal 50mg & 330mg & 40mg & 30mg cap, Cefazolin Sodium 500mg, 1g inj pws, Cefazolin 500mg, 1g inj pws, Rocephin 250mg, 10g inj pws, Ceftriaxone 250mg, 1g, 10g inj pws, Ran-Ciproflox 250mg, 500mg, 750mg tab, Novo Clonidine 0.025mg tab, Neoral 100mg/ml, Apo-Cyclosporine 100mg/ml o/l, Duragesic 12mcg trans pad, ratio-Fentanyl 12mcg trans pad, Apo-Gabapentin 600mg, 800mg tab, Diamicron MR 30mg tab ER, Apo Gliclazide MR 30mg tab ER, pms-Naproxen EC 375mg, 500mg tab ER, ratio-Pantoprazole 20mg, 40mg tab, Sandoz -Pantoprazole 20mg, 40mg tab, Co-Pantoprazole 40mg tab, Gen- Pantoprazole 40mg tab, pms-Pantoprazole 40mg tab, Seroquel 25mg, 100mg, 200mg, 300mg tab, Co Quetiapine 25mg, 100mg, 200mg, 300mg tab, Gen Quetiapine 25mg, 100mg, 200mg, 300mg tab, Novo Quetiapine 25mg, 100mg, 200mg, 300mg tab, pms Quetiapine 25mg, 100mg, 200mg, 300mg tab, ratio Quetiapine 25mg, 100mg, 200mg, 300mg tab, Gen Ramipril 1.25mg, 2.5mg, 5mg, 10mg, Valtrex 500mg, Apo Valacyclovir 500mg tab, pms Valacyclovir 500mg tab, Gen Venlafaxine XR 37.5mg, 75mg, 150mg cap SR, Sandoz Venlafaxine XR 37.5mg, 75mg, 150mg cap SR.Highlights to follow shortly.
Posted September 22, 2008
New Brunswick
Benefit Changes to NBPDP, Bulletin #727, September 18, 2008
Highlights
NBPDP Benefit Additions: ratio-Tecnal 50mg & 330mg & 40mg cap, ratio-Tecnal C1/4 50mg & 330mg & 40mg & 15mg cap, ratio-Tecnal C1/2 50mg & 330mg & 40mg & 30mg, Cefazolin 500mg, 1g inj pws, Ceftriaxone 250mg, 1g inj pws, Ran Ciproflox 250mg, 500mg, 750mg tab, Novo-Clonidine 0.025mg tab, Apo Cyclosporine 100mg/ml o/l, ratio-Fentanyl 12mcg trans pad, Apo-Gabapentin 600mg, 800mg tab, Diamicron MR 30mg tab ER, Apo Gliclazide MR 30mg tab ER, ratio-Pantoprazole 20mg, 40mg tab, Sandoz -Pantoprazole 20mg, 40mg tab, Co-Pantoprazole 40mg tab, Gen- Pantoprazole 40mg tab, pms-Pantoprazole 40mg tab, Co Quetiapine 25mg, 100mg, 200mg, 300mg tab, Gen Quetiapine 25mg, 100mg, 200mg, 300mg tab, Novo Quetiapine 25mg, 100mg, 200mg, 300mg tab, pms Quetiapine 25mg, 100mg, 200mg, 300mg tab, ratio Quetiapine 25mg, 100mg, 200mg, 300mg tab, Gen Ramipril 1.25mg, 2.5mg, 5mg, 10mg, Apo Valacyclovir 500mg tab, pms Valacyclovir 500mg tab, Gen Venlafaxine XR 37.5mg, 75mg, 150mg cap SR, Sandoz Venlafaxine XR 37.5mg, 75mg, 150mg cap SR; Non Listed Product Additions: Apo-Brimonidine P 0.15% oph sol, pms Naproxen EC 375mg, 500mg tab ER.
Posted September 17, 2008
Newfoundland
NLPDP Bulletin No. 32, Sept 16, 2008
Highlights
Correction to Vol 54 supplement. There was an error in Bulletin # 29 regarding Sandoz pramipexole. Sandoz pramipexole 0.25mg, 0.5mg, 1 mg, and 1.5mg are additions to existing categories in the NIDPF, and are NOT new categories as indicated in Bulletin #29
Posted September 15, 2008
Newfoundland
NLPDP Bulletin No. 31, Sept 12, 2008
Highlights
Additions: Sandoz Pramipexole 0.25mg, 0.5mg, 1mg & 1.5mg tabs; Apo-Desmopressin 0.1mg & 0.2mg tabs; Novo-Desmopressin 0.1mg & 0.2mg tabs; pms-Desmopressin 0.1mg & 0.2mg tabs; pms-Valacyclovir 500mg tabs; Apo-Valacyclovir 500mg tabs; Apo-Hydroxyurea 500mg caps; Apo-Cyproterone 50mg tabs; Apo-Clobazam 10mg tabs; Apo-Fluconazole-150 150mg caps; Novo-Oxycodone Acet 5mg/325mg tabs; Novo-Clonidine 0.025mg tabs; pms-Diclofenac 25mg & 50mg tabs; ratio-Morphine SR 15mg, 30mg & 60mg tabs, Ran-Ramipril 1.25mg, 2.5mg, 5mg & 10mg caps; Gen-Ramipril 1.25mg, 2.5mg, 5mg & 10mg caps; Sandoz Venlafaxine XR 37.5mg, 75mg & 150mg caps; Gen Venlafaxine XR 37.5mg, 75mg & 150mg caps; ratio-Fentanyl 12mcg/hour patch; Apo-Modafinil 100mg tabs; Apo-Ondansetron 4mg/5mL oral solution; Sandoz Cefprozil 250mg/5mL oral suspension; Apo-Gabapentin 600mg & 800mg tabs; Novo-Pantoprazole 20mg & 40mg tabs; ratio-Pantoprazole 20mg & 40mg tabs; Sandoz-Pantoprazole 20mg & 40mg tabs; pms-Pantoprazole 40mg tabs; Gen-Pantoprazole 40mg tabs; Co-Pantoprazole 40mg tabs; pms-Rabeprazole EC 10mg & 20mg tabs; Sandoz Clarithromycin 250mg & 500mg tabs.
Posted September 15, 2008
Newfoundland
NLPDP Bulletin No. 30, Sept 12, 2008
Highlights
Correction to the NIDPF: The NIDPF web listing (page 87) for Apo Timop Gel 02290812, is listed incorrectly. Bulletin #28 correctly lists this product in its appropriate category. Please refer to Bulletin #28 for details of this category while the web is being updated.
Posted September 12, 2008
Newfoundland
NLPDP Bulletin #29, September 11, 2008
Highlights
Additions to the Interchangeable Drug Products Formulary: Sandoz Pramipexole 0.25mg, 0.5mg, 1mg & 1.5mg tabs; Mirapex 0.25mg, 0.5mg, 1mg & 1.5mg tabs; Apo-Desmopressin 0.1mg & 0.2mg tabs; Novo-Desmopressin 0.1mg & 0.2mg tabs; pms-Desmopressin 0.1mg & 0.2mg tabs; DDAVP 0.1mg & 0.2mg tabs; ratio-Fentanyl 12mcg/hour patch; Duragesic 12mcg/hour patch; Apo-Modafinil 100mg tabs; Alertec 100mg tabs; Apo-Ondansetron 4mg/5mL oral solution; Zofran 4mg/5mL oral solution; pms-Valacyclovir 500mg tabs; Apo-Valacyclovir 500mg tabs; Valtrex 500mg tabs; Apo-Hydroxyurea 500mg caps; Apo-Cyproterone 50mg tabs; Apo-Clobazam 10mg tabs; Apo-Fluconazole-150 150mg caps; Novo-Oxycodone Acet 5mg/325mg tabs; Sandoz Cefprozil 250mg/5mL oral suspension; Sandoz Clarithromycin 250mg & 500mg tabs; Novo-Clonidine 0.025mg tabs; pms-Diclofenac 25mg & 50mg tabs; Apo-Gabapentin 600mg & 800mg tabs; ratio-Morphine SR 15mg, 30mg & 60mg tabs; Novo-Pantoprazole 20mg & 40mg tabs; ratio-Pantoprazole 20mg & 40mg tabs; Sandoz-Pantoprazole 20mg & 40mg tabs; pms-Pantoprazole 40mg tabs; Gen-Pantoprazole 40mg tabs; Co-Pantoprazole 40mg tabs; pms-Rabeprazole EC 10mg & 20mg tabs; Ran-Ramipril 1.25mg, 2.5mg, 5mg & 10mg caps; Gen-Ramipril 1.25mg, 2.5mg, 5mg & 10mg caps; Sandoz Venlafaxine XR 37.5mg, 75mg & 150mg caps; Gen Venlafaxine XR 37.5mg, 75mg & 150mg caps.
Posted September 10, 2008
PEI
PEI MAC Memo, Sept 2, 2008
Highlights
New interchangeable MAC Categories: Seroquel 25mg, 100mg, 200mg, 300mg tab, Ratio Quetiapine 25mg, 100mg, 200mg, 300mg tab; Products Added to the Interchangeable MAC List: Ceftriaxone 1g/vial, Gen Venlafaxine XR 37.7mg, 75mg, 150mg cap ER, Mint Citalopram 20mg, 40mg tab, Mint Ondansetron 4mg, 8mg tab, Ratio Pantoprazole 20mg tab ent, Sandoz Pramipexole 0.25mg, 0.5mg, 1mg, 1.5mg tab; Discontinued Products: Alcomicin 0.3% oph sol, Apo Levobunolol 0.5% oph sol, Novo Levobunolol 0.5% oph sol.
Posted September 10, 2008
Newfoundland
NLPDP Bulletin No. 28, September 8, 2008
Highlights
Highlights to follow shortly Prices added: Apo-Timop Gel 0.5% Oph Sol; Timol Maleate-EX Oph Sol; Timoptic-XE Oph Sol; Apo-Nizatidine Cap 150mg, 300mg; Gen-Nizatidine Cap 150mg, 300mg; Axid Cap 150mg, 300mg.
Posted September 10, 2008
British Columbia
Pharmacare Newsletter 08-009, Sept 9, 2008
Highlights
Changes in Criteria: Remicade 100ml/vial iv pws, Humira 40mg/.8ml inj-sc sol.
Posted September 3, 2008
Newfoundland
NLPDP Bulletin #27, Aug 27, 2008
Highlights
Additions: Apo-Timop 0.5% OPH SOL; Apo-Nizatidine 150mg Cap; Apo-Nizatidine 300mg Cap.
Posted September 3, 2008
Newfoundland
NLDPD Bulletin No. 26, August 27, 2008
Highlights
Additions to the Newfoundland Interchangeable Drug Products Formulary: Apo Timop 0.5% oph sol, Apo Nizatidine 150mg, 300mg cap.
Posted September 3, 2008
Nova Scotia
NS Pharmacare Bulletin Vol. #08-08, August 2008
Highlights
Criteria Change for Long Acting Bronchodilators in COPD: Spiriva, Foradil, Oxeze, Serevent, Advair, Symbicort.
Posted August 29, 2008
PEI
PEI MAC Memo, August 4, 2008
Highlights
New Products added to the MAC List: Alphagan P 0.15% oph sol, Apo Brimonidine P 0.15% oph sol, Apo Gabapentin 600mg tab, Gen Ramipril 1.25mg, 2.5mg, 5mg, 10mg cap, pms ibuprofen 400mg, 600mg tab, sandoz rabeprazole 10mg, 20mg tab ent; Changes to MAC prices: Symmetrel 10mg/ml o/syr, pms amantadine 10mg/ml o/syr.
Posted August 29, 2008
Manitoba
Manitoba Bulletin #59, September 15, 2008
Highlights
Additions: Alvesco 100mcg & 200mcg inhalers, Apo-Ondansetron 4mg/5mL oral solution, Apo-Timop 0.5% gel, Apo-Valacyclovir 500mg tablet, Ascensia Breeze 2 blood glucose test strip, Co Etindrocal 400mg/500mg tablet, Gen-Eti-Cal Carepac 400mg/500mg tablet, Novo-Morphine SR 100mg & 200mg tablets, Pms-Diclofenac 25mg & 50mg tablets, Pms-Morphine Sulfate SR 100mg & 200mg tablets, Pms-Propafenone 150mg & 300mg tablets, Pms-Valacyclovir 500mg tablets, Sandoz Paroxetine 10mg, 20mg & 30mg tablets, Sandoz Risperdone 0.25mg & 0.5mg tablets, Seroquel XR 50mg, 200mg, 300mg & 400mg tablets, Apo-Clarithromycin 250mg & 500mg tablets, Gen-Clarithromycin 250mg & 500mg tablets, Pms-Clarithromycin 250mg & 500mg tablets, Ratio-Clarithromycin 250mg & 500mg tablets, Sandoz Clarithromycin 250mg & 500mg tablets, Apo-Brimonidine P 0.15% ophthalmic solution, Apo-Modafinil 100mg tablet, Cyestra-35 2mg/0.035mg tablet, Emend 80mg, 125mg & 80/125mg capsules, Lantus 100IU/mL injection, Prezista 300mg tablet, Rilutek 50mg tablet; New Interchangeable Categories: Alphagan P 0.15% ophthalmic solution, Apo-Brimonidine P 0.15% ophthalmic solution, Rocephin 250mg, 1g & 2g injections, Ceftriaxone 250mg, 1g & 2g injections, Sandoz Ceftriaxone 1g & 2g injections, Biaxin 250mg & 500mg tablets, Apo-Clarithromycin 250mg & 500mg tablets, Gen-Clarithromycin 250mg & 500mg tablets, Pms-Clarithromycin 250mg & 500mg tablets, Ratio-Clarithromycin 250mg & 500mg tablets, Sandoz Clarithromycin 250mg & 500mg tablets, Neoral 100mg/mL oral solution, Apo-Cyclosporine 100mg/mL oral solution, Diane-35 2/0.035mg tablet, Cyestra-35 2/0.035mg tablet, Didrocal 400mg/500mg tablet, Co Etidrocal 400mg/500mg tablet, Gen-Eti-Cal Carepac 400mg/500mg tablet, Alertec 100mg tablet, Apo-Modafinil 100mg tablet, MS Contin 100mg & 200mg sustained release tablets, Novo-Morphine SR 100mg & 200mg sustained release tablets, Pms-Morphine Sulfate SR 100mg & 200mg sustained release tablets, Zofran 4mg/5mL oral solution, Apo-Ondansetron 4mg/5mL oral solution, Timoptic-XE 0.25% & 0.5% ophthalmic solutions, Timolol Maleate-EX 0.25% & 0.5% Ophtalmic solutions, Apo-Timop Gel 0.5% ophthalmic solution, Valtrex 500mg tablet, Apo-Valacyclovir 500mg tablet, Pms-Valacyclovir 500mg tablet; New Interchangeable Products: Pms-Diclofenac 25mg & 50mg tablets, Sandoz Paroxetine 10mg, 20mg & 30mg tablets, Pms-Propafenone 150mg & 300mg tablets, Sandoz Risperdone 0.25mg & 0.5mg tablets; Product Deletions: Cipro HC 2mg/10mg/mL otic solution, Clavulin 250/125mg tablet, Combivent 20/120mcg inhaler, Coryphen Codeine 325mg/30mg & 650mg/30mg tablets, Coryphen 325mg tablet, Deca-Durabolin 100mg/mL injection, Duralith 300mg tablet, Gen-Clomipramine 10mg, 25mg & 50mg tablets, Gen-Diltiazem 30mg & 60mg tablets, Losec Mups 10mg & 20mg tablets, Monurol 3g powder, Neosporin cream, Nitrazadon 5mg & 10mg tablets, Norpramin 75mg tablet, Novolin ge 10/90 100IU/mL injection, Novolin ge 20/80 100IU/mL injection, Novo-Clopate 3.75mg. 7.5mg & 15mg capsules, Novo-Dipam 2mg, 5mg & 10mg tablets, Novo-Misoprostol 100mcg & 200mcg tablets, Novo-Pramine 10mg, 25mg & 50mg tablets, Novo Propamide 250mg tablet, Nozinan 2mg tablet, Nozinan 40mg/mL & 5mg/mL liquids, Orifer F tablet, Ortho-Cept 21 tablet, Ostoforte 50000IU capsule, Pancrease capsule, Panoxyl 15% Gel, Parlodel 2.5mg tablet, Permax 0.05mg, 0.25mg & 1mg tablets, Premarin 0.9mg tablet, Sandoz Gliclazide 80mg tablet, Sandoz Risperdone 0.25mg & 0.5mg tablets, Schienpharm Testone-Cyp 100mg/mL injection, Stevia-A 0.01% gel, Sulphated Insulin 100IU/mL injection, Synamol 0.025% cream, Synamol regular 0.025% cream, Testosterone 200mg/mL injection, Trasicor 80mg tablet, Triphasil 21 tablet, Triphasil 28 tablet, Zinacef 1.5g & 7.5g injections; Category Deletions: Clorazepate Dipotassium 3.75mg, 7.5mg & 15mg capsules, Fluvoxate HCL 200mg tablet, Imipramine HCL 10mg tablet, Lithium Carbonate 300mg tablets, Misoprostol 100mcg tablet, Perindopril 8mg tablet; Price Changes: Betagan 0.5% ophthalmic solution, Betaject 6mg/mL injection, Cortenema 100mg enema, Ceftin 250mg & 500mg tablets, Cefzil 250mg & 500mg tablets, Cefzil 125mg/5mL & 250mg/5mL oral suspensions, Clavulin 125mg/31.25mg/5mL, 250mg/62.5mg/5mL & 400mg/57mg/5mL oral suspensions, Clavulin 500mg & 875mg tablets, CoActifed Syrup, Cortisporin otic solution, Coumadin 1mg, 2mg, 2.5mg, 3mg, 4mg, 5mg & 10mg tablets, Cytoxan 50mg tablet, Desyrel 50mg, 100mg & 150mg tablets, Gen-Budesonide AQ 64mcg nasal spray, Gen-Clozapine 25mg & 100mg tablets, Hydrea 500mg capsule, Imitrex DF 50mg & 100mg tablets, Imuran 50mg tablet, K-10 solution 1.33mEq/mL oral liquid, Lamictal 25mg, 100mg & 150mg tablets, Megace 160mg tablet, Modecate 100mg/mL injection, Modulon 200mg tablet, Monopril 10mg & 20mg tablets, Paxil 10mg, 20mg & 30mg tablets, Percocet 5/325mg tablet, Percodan 5/325mg tablet, Pms-Mirtazapine 30mg tablet, Pravachol 10mg, 20mg & 40mg tablets, Retrovir 100mg capsule, Sandoz Anuzinc 0.5% ointment, Sandoz Anuzinc 10mg suppositories, Sandoz Bupropion 100mg tablet, Sandoz Citalopram 20mg & 40mg tablets, Sandoz Famciclovir 125mg, 250mg & 500mg tablets, Sandoz Fenofibrate S 100mg & 160mg tablets, Sandoz Lisinopril 5mg tablet, Sandoz Pravastatin 10mg, 20mg & 40mg tablets, Sandoz Sertraline 25mg, 50mg & 100mg capsules, Sandoz Zopiclone 5mg tablet, Sinemet 100/10mg, 100/25mg & 250/25mg tablets, Sulcrate 1g tablet, Symmetrel 10mg/mL syrup, Symmetrel 100mg capsule, Ventolin 2mg/mL & 1mg/mL nebules, Ventolin 0.4mg/mL oral liquid, Voltaren Rapide 50mg tablet, Voltaren SR 75mg & 100mg tablets, Zantac 15mg/mL oral solution, Zantac 150mg & 300mg tablets, Zofran 4mg & 8mg tablets, Zovirax 200mg, 400mg & 800mg tablets, Zyloprim 300mg tablet; Discontinued Products: Apo-Cromolyn 1% inhalation solution, Apo-Salvent Ipravent 1mg/0.2mg/mL liquid, Climacteron injection, Co Buspirone 10mg tablet, Novo-Levobunolol 0.25% & 0.5% ophthalmic solution, Sandoz Gliclazide 80mg tablet.
Posted August 29, 2008
Non-Insured Health Benefit Program (NIHB)
Updates to the NIHB Drug Benefit List, Summer 2008
Highlights
Open Benefit Additions: 76 additions, See bulletin for list; Limited Use Addtions: Co Cabergoiline 0.5mg tab, Apo Pantoprazole 40mg tab, Gen Pantoprazole 40mg tab, Novo Pantoprazole 40mg tab, Ran Pantoprazole 40mg tab, Ratio Pantoprazole 40mg tab, Sandoz Pantoprazole 40mg tab; Products Not Added to the Formulary: Apo Ciclopirox top sol, Gen Zopiclone 5mg tab, Pseudofrin 60mg tab, Riva Buspirone 10mg tab, Riva Dicyclomine 10mg tab, Triatec 8, Triatec 8 Strong; Drugs Excluded from the NIHB Drug Benefits List: Apo Pantoprazole 20mg tab, Damylin with Codeine Syrup, Novo Pantoprazole 20mg tab, Ran Pantoprazole 20mg tab, Ratio Pantoprazole 20mg tab, Sandoz Pantoprazole 20mg tab, Trianal c1/2 cap, Trianal c1/4 cap, Trianal cap, Trianal tab; Drugs Discontinued by the Manufacturer: Apo Midodrine 2.5mg, 5mg tab, Apo Salvent 0.5mg/ml, 1mg/ml, 2mg/ml, Apo Salvent-Ipravent 1mg % 0.2mg/ml sterules, Depakene 500mg cap, Novo Cyproterone 50mg tab, Novo Levobunolol 0.25%, 0.50% opth sol, PCE 333mg tab, Pediazole 40mg & 120mg/ml o/susp; Name Changes: Derma Smoothie 0.01% top sol, Zapex 10mg, 15mg, 30mg tab; Manufacturer Change: Micro K ExtenCaps 600mg cap; Corrections to the Drug Benefit List: Botox 100u inj sol, Sutent 12.5mg, 25mg, 50mg cap.
Posted August 22, 2008
Ontario
ODB, Edition 41 Update A, effective Aug 28, 2008
Highlights
New Single Source Drugs: Combigan 0.2% & 0.5% Oph Sol; Humalog Mix50 50% & 50% Inj Susp; Risperdal Consta 25mg Pd for Inj-Vial Pk; Risperdal Consta 37.5mg Pd for Inj-Vial Pk; Risperdal Consta 50mg Pd for Inj-Vial Pk. New Multi-Source Drugs: Co Pantoprazole 40mg Ent Tab; Gen-Pantoprazole 40mg Ent Tab; PMS-Pantoprazole 40mg Ent Tab; Ratio-Pantoprazole 40mg Ent Tab; Sandoz Pantoprazole 40mg Ent Tab; Apo-Gliclazide MR 30mg SR Tab; Apo-Valacyclovir 500mg Tab; Ceftriaxone for Injection USP 0.25g/vial Inj Pd-1 Vial Pk; Gen-Ramipril Cap 1.25mg; Gen-Ramipril Cap 2.5mg; Gen-Ramipril Cap 5mg; Gen-Ramipril Cap 10mg; Gen-Venlafaxine XR 37.5mg ER Cap; Gen-Venlafaxine XR 75mg ER Cap; Gen-Venlafaxine XR 150mg ER Cap; Mint-Citalopram 20mg Tab; Mint-Citalopram 40mg Tab; PMS-Rabeprazole EC 10mg Tab; PMS-Rabeprazole EC 20mg Tab; PMS-Valacyclovir 500mg Tab; Ramipril Cap 1.25mg; Ramipril Cap 2.5mg; Ramipril Cap 5mg; Ramipril Cap 10mg; Sandoz Brimonidine 0.2% Oph Sol; Sandoz Clarithromycin 250mg Tab; Sandoz Risperidone 0.25mg Tab; Sandoz Risperidone 0.5mg Tab; Sandoz Venlafaxine XR 37.5mg ER Cap; Sandoz Venlafaxine XR 75mg ER Cap; Sandoz Venlafaxine XR 150mg ER Cap. Exceptional Access Product: Betaseron 9,600,000IU Inj Pref Syr-0.3mg Pk. Facilitated Access Drug – HIV/AIDS: Atripla 600mg/300mg/200mg Tab. Manufacturer Requested Discontinued Drugs: 19 Drugs (Please see bulletin for Full Listing). Drug Benefit Prices: 28 Prices (Please see bulletin for Full Listing). New Manufacturer Name: Morphine Sulfate Injection USP 15mg/ml Inj Sol Amp. Not-A-Benefit Drugs: Clavulin 250mg & 125mg Tab; Norpramin 25mg Tab; Norpramin 50mg Tab; Nozinan 5mg Tab; Nozinan 25mg Tab; Nozinan 50mg Tab; Parlodel 2.5mg Tab; Rhodis-EC 100mg Ent Tab; Rhotrimine 75mg Cap; Rhotrimine 100mg Tab; Tofranil 25mg Tab. Off Formulary Interchangeable Products: 12 Products (Please see bulletin for Full Listing). Discontinued Drugs: Novo-Citalopram 20mg Tab; Ortho-Cept 0.15mg & 0.03mg Tab-21 Pk; Panoxyl 15% Gel. Not-A-Benefit Drugs Removed from listing: Artane 0.4mg/ml; Decadron 0.1% Oph/Ot Sol; Feldene 10mg Sup. Status Changes from Limited Use to General Benefit: Humalog Mix25 25% & 75% Inj Susp-5X3ml Pk; Humalog 100U/ml Inj Sol-5X3ml Pk; 100U/ml Inj Sol-10ml Pk. New Diabetic Testing Agent: Freestyle Lite Blood Glucose Strip.
Posted August 22, 2008
Newfoundland
NLPDP Benefit List - effective Aug 1, 2008
Highlights
Highlights to follow shortly.
Posted August 15, 2008
British Columbia
BC Pharmacare Newsletter 08-008, Effective Aug 15, 2008
Highlights
Benefits: Advicor 100mg/40mg Tab; Osto-D2 50,000IU Cap; Seroquel XR 50mg Tab; Seroquel XR 200mg Tab, Seroquel XR 300mg Tab; Seroquel XR 400mg Tab; Tiazac XC 120mg Tab; Tiazac XC 180mg Tab; Tiazac XC 240mg Tab; Tiazac XC 300mg Tab; Tiazac XC 360mg Tab. Blood Glucose Monitoring Strip Benefits: Freestyle Lite Blood Glucose Test Strips. Limited Coverage Program: Diamicron 80mg Tab; Hyzaar 100mg/12.5mg Tab. Non-Benefits: Apo-Ciclopirox 8% Top Sol; Pms-Olanzapine 2.5mg Tab; PMS-Olanzapine 5mg Tab; PMS-Olanzapine 7.5mg Tab; PMS-Olanzapine 10mg Tab; PMS-Olanzapine 15mg Tab; Novo-Olanzapine 2.5mg Tab; Novo-Olanzapine 5mg Tab; Novo-Olanzapine 7.5mg Tab; Novo-Olanzapine 10mg Tab; Novo-Olanzapine 15mg Tab; Co-Cabergoline 0.5mg Tab; Zymar 0.3% Oph Sol.
Posted August 6, 2008
Alberta
Additions - Changes to Special Authority Criteria, effective Aug 1, 2008
Highlights
Criteria changes to: Humira, Remicade
Posted August 6, 2008
Alberta
Additions to AHWDBL, effective Aug 1, 2008
Highlights
Highlights to follow shortly
Posted August 1, 2008
New Brunswick
Benefit Changes to NBPDP Bulletin #721, July 30, 2008
Highlights
Highlights to follow shortly
Posted July 28, 2008
Nova Scotia
NS Pharmacare Bulletin #08-07 July 2008
Highlights
Highlights to follow shortly
Posted July 22, 2008
Québec
Modification No 1 and Correction #2 of the Liste de Medicaments, effective July 16, 2008
Highlights
Additions: MS Contine 200mg Tab; pms-Olazapine 2.5mg, 5mg, 7.5mg, 10mg, 15mg Orl Dis Tab; Aldactazide 50 50mg/50mg Tab
Posted July 22, 2008
Québec
Correction No 3 of Liste de Medicaments, effective July 18, 2008
Highlights
Price changes: pms-Naproxen EC 375mg, 500mg Tabs; AndroGel 1% Top Gel
Posted July 16, 2008
Alberta
Alberta Health and Wellness Drug Benefit List, July 1, 2008
Highlights
Full Release.
Posted July 10, 2008
Prince Edward Island
PEI update to MAC List - July 21, 2008
Highlights
New Interchangeable/MAC Categories: Anagrelide 0.5mg Cap; Ceftriaxone 1.0g/vial Inj; Fentanyl 12UG/HR Trans Patch; Gliclazide 30mg Tab ER. Products to be added to the Interchangeable/MAC List: Citalopram-Odan 20mg, 40mg Tab; Co Pantoprazole 40mg Tab Ent; Gen-Eti-Cal Carepac Kit; Gen-Pantoprazole 40mg Tab Ent; Novo-Clonidine 0.025mg Tab; Odansetron-Odan 4mg, 8mg Tab; Pms-Pantoprazole 40mg Tab Ent; Ratio-Pantoprazole 40mg Tab Ent; Sandoz Clarithromycin 250mg, 500mg Tab; Sandoz Pantoprazole 20mg, 40mg Tab Ent; Sandoz Paroxetine 20mg, 30mg Tab. Deleted Interchangeable/MAC Categories: Perindopril 8mg Tab. Discontinued Products: Sandoz Paroxetine 20mg, 30mg Tab; Tantum Oral Rinse.
Posted July 9, 2008
Saskatchewan
Saskatchewan Formulary 58th Edition - July 2008 - June 2009
Highlights
New Full Formulary Listings: FreeStyle Lite-ABB; pms-Amiodarone-PMS. New Exception Drug Status Listings: Raptiva-SRO 150mg/vial PWS; Enbrel-AMG 25mg/vial Inj Pd, 50mg/ml pre-filled syringe; Remicade-SCH 100mg/vial Inj. Drugs Currently Under Review by the Saskatchewan Review Committee: Atripla; Campral; Invega; Isentress; Lucentis; Ralivia; Tridural. New Full Formulary Non-Interchangeable Listing Effective February 15, 2008: pms-Hydromorphone-PMS 3mg Rect Supp. New Interchangeable Listings Effective May 1, 2008: CO Etidrocal-COB 400mg/1250mg Tab; Gen-Eti-Cal Carepac-GPM 400mg/1250mg Tab; Dom-Lisinopril-DOM 5mg, 10mg, 20mg Tab; Sandoz Metoprol SR-SDZ 100mg, 200mg Tab SR; pms-Morphine Sulfate SR-PMS 150mg, 300mg Tab; pms-Propafenone-PMS 150mg, 300mg Tab; Ramipril-PMS 1.5mg, 2.5mg, 5mg, 10mg Cap; Sodium Sulamyd-SDZ 10% Oph Sol; CO Venlafaxine XR-COB 37.5mg, 75mg, 150mg Cap. New Interchangeable EDS Listings Effective May 1, 2008 According to Current EDS Criteria: Novo-Pantoprazole-NOP 40mg Tab. New Interchangeable Listing Effective June 1, 2008: pms-Valacyclovir-PMS 500mg Caplt. New Interchangeable Listings Effective July 1, 2008: Dom-Doxycycline-DOM 100mg Cap, 100mg Tab; Dom-Levetiracetam-DOM 250mg, 500mg, 750mg Tab. New Interchangeable EDS Listings Effective July 1, 2008 According to Current EDS Criteria: Dom-Azithromycin-DOM 250mg, 500mg Tab; CO Fluconazole-COB 50mg, 100mg Tab; Apo-Modafinil-APX 100mg Tab.
Posted July 4, 2008
Saskatchewan
Saskatchewan Bulletin #115, July 2008
Highlights
New Full Formulary Listings: Free Style Lite Blood Glucose Test Strip, pms Amoodarone 100mg tab; New Exception Drug Status: Raptiva 150mgvial pws, Enbrel 25mg/vail, prefilled syringe, 50mg/ml inj pws, Remicade 100mg/vial; Drugs Currently Under Review: Atripla, Campral, Invega, Isentress, Lucentis, Ralivia, Tridural; New Full Formulary Non Interchangeable Listings: pms Hydromorphone 3mg supp; New Interchangeable Listings: Co Etidrocal 400mg & 1250mg tab, Gen Eti Cal Carepac 400mg & 1250mg tab, Dom Lisinopril 5mg, 10mg, 20mg tab, Sandoz Metoprol SR 100mg, 200mg tab SR, pms Morphine Sulfate 100mg, 200mg tab SR, pms Propfenone 150mg, 300mg tab, Ramipril 1.5mg, 2.5mg, 5mg, 10mg cap, Sandoz Risperidone 0.25mg, 0.5mg tab, Sodium Sulamyd 10% oph sol, Co Venlafaxine XR 37.5mg, 75mg, 150mg cap; New Interchangeable EDS Listings: Ran Ciproflox 250mg, 500mg, 750mg tab, Novo Pantoprazole 10mg tab; New Interchangeable Listings: pms Valacyclovir 500mg cap, Dom Doxycycline 100mg tab, 100mg cap, Dom Levetiracetam 250mg, 500mg, 700mg tab; New Interchangeable EDS Listings: Dom Azithromycin 250mg, 500mg tab, Co Fluconazole 50mg, 100mg tab, Apo Modafinil 100mg tab; Additions: pms Valacyclovir 500mg tab, Strattera 10mg, 18mg, 25mg, 40mg, 60mg cap, Citalopram Odan 20mg, 40mg tab, Sandoz Clarithromycin 250mg, 500mg tab, Novo Clonidine 0.025mg tab, Concerta 18mg, 27mg, 36mg, 54mg tab, Co Pantoprazole 40mg tab ent, Gen Pantoprazole 40mg tab ent, pms Pantoprazole 40mg tab ent, ratio Pantoprazole 40mg tab ent, Sandoz Pantoprazole 40mg tab ent, pms Rabeprazole 10mg, 20mg tab ent, Apo Valacyclovir 500mg tab, Gen Venlafaxine XR 37.5mg, 75mg, 150mg cap, Sandoz Venlafaxine XR 75mg, 150mg cap; Discontinued by the Manufacturer: Nitrazadon 5mg, 10mg tab; Additions to the EDS: Strattera 10mg, 18mg, 25mg, 40mg, 60mg cap, Clarithromycin 250, 500mg tab, Sandoz Clonidine HCL 0.025mg tab, Novo Clonidine 0.025mg tab, Remicade 100mg/vial; Price Changes: Renagel 800mg tab, Flovent HFA 125ug inh aem.
Posted July 2, 2008
Alberta
AHWDBL and AEIIDBS Quarterly Updates, July 1, 2008
Highlights
AEIIDBS; Additions: Boost Diabetic o/l, Vicks Childrens Nyquill Cold and Cough o/l; Additions considered for special authorization coverage: Raptiva 150mg/vial inj, Eprex 30 000 u/0.75ml inj; Changes to Criteria: Enbrel 25mg/vial, 50mg/ml inj, Rilutek 50mg tab; Products considered for Optional Special Authorization: Ran Ciproflox 250mg, 500mg, 750mg tab; AHWDBL: Additions: Apo Lisinopril 20mg & 12.5mg, 20mg & 25mg tab, Co Fluconazole 50mg, 100mg tab, Co Venlafaxine XR 150mg, 37.5mg, 75mg cap, Gen Lisinopril 10mg & 12.5mg, 20mg & 12.5mg, 20mg & 25mg tab, Novo Atenolthalidone 50mg & 25mg, 100mg & 25mg tab, Novo Citalopram 40mg tab, Novo Lisinopril HCTZ (type P) 10mg & 12.5mg, 20mg & 25mg, Novo Lisinopril HCTZ (type Z) 10mg & 12.5mg, 20mg & 12.5mg, 20mg & 25mg tab, Novo Morphine SR 60mg tab SR, pms Bisoprolol 5mg, 10mg tab, pms Clindamycin 150mg, 300mg cap, pms Desmopressin 0.1mg, 0.2mg tab, pms Digoxin 0.0625mg tab, pms Gliclazide 80mg tab, pms Minocycline 50mg cap, Sandoz Brimonidine 0.2% oph sol, Sandoz Cefprozil 250mg, 500mg tab, Sandoz Lisinopril HCT 10mg & 12.5mg, 20mg & 12.5mg, 20mg & 25mg tab; Discontinued Listings: Apo Cromolyn Sterules 1% inh sol, Apo Salvent Sterules 1mg/ml, 1.25mg/ 2.5ml, 2mg/ml inh sol, Depakene 500mg cap ent, Froben SR 200mg cap SR, Halog 0.1% top crm, Novo Cimetine 200mg, 800mg tab, Novo Clopate 3.75mg, 7.5mg, 15mg cap, Novo Levobunolol 0.25%, 0.5% oph sol, Ratio Valproic 500mg cap ent; Additions considered for special authorization coverage: Raptiva 150mg/vial inj, Eprex 30 000 u/0.75ml inj; Changes to Criteria: Enbrel 25mg/vial, 50mg/ml inj, Rilutek 50mg tab; Discontinued Special Authorization Drugs: Desquam-X 10% top gel, Novo Cyproterone 50mg tab; Products considered for Optional Special Authorization: Ran Ciproflox 250mg, 500mg, 750mg tab
Posted June 27, 2008
British Columbia
BC Pharmacare Newsletter #08-007, June 27, 2008
Highlights
Expanded Coverage of Biologics for Rheumatoid Arthritis effective June 30, 2008: Orencia 250MG/VIAL; Rituxan 10MG/ML IV PWS. Update Re Olanzapine Table Coverage: Zyprexa 2.5mg, 5mg, 10mg, 15mg Tab.
Posted June 25, 2008
Alberta
Special Authorization Drug Products with Changes to Criteria, effective June 1, 2008
Highlights
Criteria changes to: Humira 40mg/syringe inj sol; Enbrel 25mg/vial, 50mg/syr inj sol.
Posted June 20, 2008
Ontario
ODB Edition 40, Update 13, effective June 27, 2008
Highlights
New Single Source Drug(s): Seroquel XR 50mg, 200mg, 300mg, 400mg Tab ER. New Multi-source Drug(s): Co Etidrocal 400mg/500mg Tab Kit; Gen-Eti-Cal Carepac 400mg/500mg Tab Kit; Novo-Pantoprazole 40mg Tab Ent; Pms-Gliclazide 80mg Tab; Pms-Morphine Sulfate SR 100mg, 200mg Tab; Sandoz Metoprolol SR 100mg, 200mg Tab. Discontinued by Manufacturer: Apo-Salvent Sterule 1mg/ml, 2mg/ml Inh Sol 2.5ml Pk; Capoten 100mg Tab; Desquam-X10 10% Gel; Froben 50mg Tab; Halog 0.1% Cr; Halog 0.1% Oint; K-Lor 20mEq/Pouch Oral Pd-3 Pk; Novo-Clopate 3.75mg, 7.5mg, 15mg Cap; PCE Dispertab 333mg Tab; Pediazole 40mg & 120mg/ml O/L; PMS-Propafenone 150mg, 300mg Tab; Sustiva 100mg Cap; Westcort 0.2% Oint. Price Changes: Aristocort R 0.1% Cr; Aristocort R 0.1% Oint; Cuprimine 250mg Cap; Diovan 320mg Tab; Viread 300mg Tab. Off Formulary Interchangeable Product(s): Apo-ISMN 60mg Tab ER; Apo-Lithium Carbonate SR 300mg Tab; Apo-Mondafinil 100mg Tab; Apo-Oxcarbazepine 150mg, 300mg, 600mg Tab; Apo-Pantoprazole 20mg Tab ENT; Apo-Tryptopham 500mg Cap; Apo-Tryptopham 500mg, 1g Tab; Cefoxitin for Injection 1g/vial, 2g/vial Inj Pd – 1 Vial Pk; Co Alendronate 40mg Tab; Co Azithromycin 600mg Tab; Co Cabergoline 0.5mg Tab; Gen-Warfarin 6mg Tab; Sandoz Calcitonin NS 200U/metered dose Nas Sp - 2X14 Dose Pk.
Posted June 19, 2008
Newfoundland
Correction to Bulletin #15 - Dated May 12, 2008
Highlights
New Category to Vol. 54 NIDPF - effective July 1, 2008: Sandoz-Omeprazole 10mg Cap; Losec 10mg Tab. Previously reported as addition to existing category, now corrected to report New Category
Posted June 19, 2008
Nova Scotia
NS Pharmacare Bulletin #08-06, June 2008
Highlights
Discontinued: Novo-Cimetine 800mg Tab: Novo-Clopate 3.75mg, 7.5mg, 15mg Cap; Froben SR 200mg Cap; Herplex-D 0.1% Sol; Novo-Misoprostol 100mcg Tab; Sufenta 50mcg/ml Inj. New Diabetic Products: Novamax Test Strips 50/box, 100/box; On-Call Plus Test Strips 25/box, 50/box, 100/box. New Products: Apo-Timop 0.5% Oph Gel. Interchangeable Products Added to the Formulary: Novo-Oxycodone Acet 5mg & 325mg Tab; Gen-Bicalutamide 50mg Tab; RAN-Ciproflox 250mg, 500mg, 750mg Tab; MINT-Citalopram 20mg, 40mg Tab; Sandoz Metoprolol SR 100mg, 200mg Tab; pms-Morphine Sulfate SR 100mg, 200mg Tab; pms-Olanzapine 2.5mg, 5mg, 7.5mg, 10mg, 15mg Tab; Novo-Pantoprazole 20mg, 40mg EC TAb; pms-Propafenone 150mg, 300mg Tab; Sandoz Risperidone 0.25mg, 0.5mg Tab. New Categories: Apo-Ciclopirox 8% Top Sol; Penlac 8% Top Sol; CO Etidrocal 400mg & 500mg Tab; Didrocal 400mg & 500mg Tab; Gen-Eti-Cal Carepac 400mg & 500mg Tab; Apo-Modafinil 100mg Tab; Alertec 100mg Tab.
Posted June 17, 2008
New Brunswick
NBPDP Bulletin #718, June 16, 2008
Highlights
Benefit Status Change for Omeprazole and Rabeprazole: Losec 20mg Cap; Apo-Omeprazole 20mg Cap; Sandoz-Omeprazole 20mg Cap; Losec 20mg Tab; ratio-Omeprazole 20mg Tab; Pariet 10mg, 20mg Tab; Novo-Rabeprazole 10mg, 20mg Tab; Ran-Rabeprazole 10mg, 20mg Tab.
Posted June 12, 2008
British Columbia
BC Pharmacare Newsletter Edition 08-006, June 12, 2008
Highlights
New Drugs Categorized to LCA and/or RDP: Novo-Citalopram 40mg, 20mg Tab; PMS-ISMN SR 60mg Tab; PMS-Temazepam 15mg, 30mg Cap; PMS-Minocycline 50mg, 100mg Cap; PMS-Clindamycin 150mg, 300mg Cap; Co-Venlafaxine 37.5mg, 75mg, 150mg Cap; Co-Fluconazole 50mg, 100mg Tab; PMS-Gliclazide 80mg Tab; Sandoz Brimonidine 0.2% OPH SOL. Benefits Palliative Care Drug Plan: Ran-Rabeprazole 10mg, 20mg Tab; Novo-Rabeprazole EC 10mg, 20mg Tab, Co-Fluconazole 50mg, 100mg Tab. Non-Benefits: Apo-Bicalutamide 50mg Tab; Gen-Bicalutamide 50mg Tab.
Posted June 3, 2008
New Brunswick
Bulletin #716, Benefit Changes to NBPDP, June 2, 2008
Highlights
Interchangeable Product Additions: Novo Oxycodone Acet 5mg & 325mg tab, Sandoz Bromide 0.2% oph sol, Dostinex 0.5mg tab, Co Cabergoline 0.5mg tab, Mint Citalopram 20mg, 40mg tab, pms Deferoxamine 2g pws inj, Sandoz Metoprolol SR 100mg, 200mg tab sr, Novo Morphine SR 60mg, 100mg, 200mg tab sr, pms Morphine Sulfate SR 100mg, 200mg tab sr, pms Olanzapine 2.5mg, 5mg, 7.5mg, 10mg, 15mg tab, Apo Ondansetron 4mg/5ml o/l, Apo Pantoprazole 20mg, 40mg tab dr, Novo Pantoprazole 20mg, 40mg tab dr, Ran Pantoprazole 20mg, 40mg tab dr, pms Propafenone 150mg, 300mg tab, Ramipril 2.5mg, 5mg, 10mg cap, Sandoz Risperidone 0.5mg tab, Apo Timop Gel 0.5% oph sol, Co Venlafaxine XR 37.5mg, 75mg, 150mg cap er, Apo Ciclopirox, 8% top sol, Apo Modafinil 100mg tab, Penlac 8% top sol, Alertec 100mg tab, MS Contin 100mg, 200mg tab, Zofran 4mg/5ml o/l, Pantoloc 20mg, 40mg tab dr
Posted June 3, 2008
Prince Edward Island
PEI MAC Memo - June 2008
Highlights
New Interchangeable/MAC Categories: Modafinil 100mg Tab; Valacyclovir 500mg Caplt. Products to be added to the Interchangeable/MAC List: Novo-Oxycodone Acet 5mg, 325mg Tab. Deleted Interchangeable/MAC Categories: Clorazepate Dipotassium 3.75mg, 7.5mg, 15mg Cap. Discontinued Products: Apo-Salvent Sterules 0.5mg/ml, 1mg/ml, 2mg/ml Inh Sol; Capoten 100mg Tab; Depakene 500mg Cap; Novo-Levobunolol 0.25% Oph Sol.
Posted June 3, 2008
Newfoundland
Newfoundland Bulletin #17, May 23, 2008
Highlights
Status Corrected by Province: Risperdal M 2mg Tab
Posted June 2, 2008
Alberta
Additions to AHWDBL June 1, 2008
Highlights
New Drug Products Added to the AHWDBL: Co Etidirocal 400mg/500mg Tab; Gen-Eti-Cal Carepac 400mg/500mg Tab; Didrocal 400mg/500mg Tab; Apo-Pantoprazole 40mg Tab EC; Ran-Pantoprazole 40mg Tab EC; Pantoloc 40mg Tab EC; PMS-Olanzapine 2.5mg, 5mg, 7.5mg, 10mg, 15mg Tab; Novo-Olanzapine 2.5mg, 5mg, 7.5mg, 10mg, 15mg Tab; Zyprexa 2.5mg, 5mg, 7.5mg, 10mg, 15mg Tab.
Posted June 2, 2008
Québec
Liste de medicaments & capsule - June 2008
Highlights
Declined due to economic and pharmacoeconomic reasons: Aclasta 5mg/100ml iv sol, Actonel 75mg tab, Cubicin 500mg inj pws, Eraxis 100mg inj pws; Declined due to therapeutic value: Frova 25mg tab, Invega 3mg, 6mg, 9mg tab ER, Ralivia 100mg, 200mg, 300mg tab ER, Sebivo 600mg tab, Tridural 100mg, 200mg, 300mg tab ER, Zytram XL 150mg, 200mg, 300mg, 400mg tab ER; Criteria Change: Advair 125, Advair 250, Advair 100 Diskus, Advair 250 Diskus, Advair 500 Diskus inh aem, Symbicort 100 Turbuhaler, Symbicort 200 Turbuhaler inh pd, Cancidas 50mg, 70mg inj pws; Criteria Change for Nutritional Products: Optimental o/l, Perative o/l, Peptamen o/l, Peptamen AF o/l, Peptamen 1.5 o/l, Peptamen JR o/l, Peptamen with Prebio 1 o/l, Peptinex o/l, Peptinex DT o/l, Peptinex DT Pediatric o/l, Peptinex 1.5 o/l, Vital HN o/pd, Tolerex o/pd, Vivonex Pediatric o/pd, Vivonex Plus o/pd, Vivonex TEN o/pd; Additions: Atripla 200mg, 300mg, 600mg tab, Campral 333mg tab ER, Cymbalta 30mg, 60mg cap ER, Enbrel and Enbrel SureClick 25mg/vial, 50mg/vial inj-sc pws, Remicade 100mg/vial iv pws, Mycamine 50mg inj pws, Rituxan 10mg/ml inj sol, Suboxone 2mg & 0.5mg, 8mg & 2mg tab SL, Zeldox 20mg, 40mg, 60mg, 80mg cap
Posted May 30, 2008
British Columbia
BC Pharmacare Newsletter Edition 08-005, May 28, 2008
Highlights
Benefits: Advicor 500mg/20mg ,1000mg/20mg Tabs. Limited Coverage: Lantus Solostar 100U/ml - 3ml pre-filled pen; Oxycontin 5mg Tab CR. Non Benefits: Pegasys 180ug/0.5ml, 180ug/ml for treatment of cronic Hepatitis B; Sebivo 600mg Tab; Tysabri 300mg/15ml vial (IV); Uromax 10mg, 15mg Tab CR. LCA/RDP Booklet changes. See update for details.
Posted May 28, 2008
NIHB
Updates to the Drug Benefit List Spring 2008
Highlights
Open Benefits-Single-Source Drug Products: Hyzaar 100mg/12.5mg Tab; Metrogel 1% Top Gel Open Benefit-Multi-Source Drug Products: Apo-Lisinopril HCTZ 20/12.5mg, 20/25mg Tab; Gen-Atenolol 25mg Tab; Gen-Bicalutamide 50mg Tab; Gen-Lisinopril HCTZ 10/12.5mg, 20/12.5mg, 20/25mg Tab; Gen-Metoprolol 25mg Tab; Novo-Atenolthalidone 100mg/25mg, 50mg/25mg Tab; Novo-Lisinopril HCTZ P 10/12.5mg, 20/12.5mg, 20/25mg Tab; Novo-Lisinopril HCTZ Z 10/12.5mg, 20/12.5mg, 20/25mg Tab; Novo-Rabeprazole 10mg, 20mg Tab; PMS-Bisoprolol 10mg, 5mg Tab; PMS-Clindamycin 150mg, 300mg Cap; PMS-Desmopressin 0.1mg, 0.2mg Tab; PMS-Gliclazide 80mg Tab; PMS-Naproxen EC 375mg, 500mg Tab; PMS-Temazepam 15mg, 30mg Cap; RAN-Ciproflox 250mg, 500mg, 750mg Tab; RAN-Rabeprazole 10mg, 20mg Tab; Sandoz Brimonidine 0.2% Oph Sol; Sandoz Cefprozil 125mg/5ml, 250mg/5ml Orl Susp, 250mg, 500mg Tab; Sandoz Lisinopril HCTZ 10/12.5mg, 20/12.5mg, 20/25mg Tab. New Limited Use Benefit: Co-Cabergoline 0.5mg Tab; PMS-Minocycline 100mg, 50mg Cap; Apo-Pioglitazone 15mg, 30mg, 45mg Tab; Co-Pioglitazone 15mg, 30mg, 45mg Tab; Gen-Pioglitazone 15mg, 30mg, 45mg Tab; Novo-Pioglitazone 15mg, 30mg, 45mg Tab; PMS-Pioglitazone 15mg, 30mg, 45mg Tab; Ratio-Pioglitazone 15mg, 30mg, 45mg Tab; Sandoz Pioglitazone 15mg, 30mg, 45mg Tab. Special Formulary for Chronic Renal Failure: Eprex 20,000IU/0.5ml Prefilled Syr. Not Added to Formulary: Clobex 0.05% Spray. Drugs Discontinued by the Manufacturer: Apo-Midorine 2.5mg, 5mg Tab; Apo-Naproxine SR 750mg Tab; Dexasone 0.5mg Tab; Duonalc Solution 70% 100ml; Froben 100mg Tab; Gen-Clomipramine 10mg, 25mg, 50mg Tab; Gen-Diltiazem 30mg, 60mg Tab, Hydromorph-IR 2mg, 4mg, 8mg Tab; Micro-K Extencaps 600mg Cap; Multi-Tar Plus Herbal 150ml; Novo-Misoprostol 100mcg Tab; Novo-Ramipril 1.25mg Cap; Oxybutyn 5mg Tab; Pancrease EC Cap; Ratio-Sulfasalazine 500mg Tab; Ratio-Sulfasalazine EN 500mg Tab.
Posted May 28, 2008
Nova Scotia
Pharmacare Bulletin #08-05, May 2008
Highlights
New Products and Special MACs: Metadol 1mg/ml, 10mg/ml O/L, Methadone for O/L compound; New Products: Elaprase 2mg/ml inj, Eprex 20 000u/0.5ml inj, Fosrenol 250mg, 500mg, 750mg, 1000mg tab, Hyzaar 100/12.5mg tab, Spriafil 40mg/ml susp, Sprycel 20mg, 50mg, 70mg tab, Thelin 100mg cap; New Criteria: Sprycel 20mg, 50mg, 70mg tab; Addition to Criteria: Sutent 12.5mg, 25mg, 50mg cap; Changes in Criteria: Duragesic 25 2.5mcg/hr trans pad, Duragesic 50 5mcg/hr trans pad, Duragesic 75 7.5mcg/hr trans pad, Duragesic 100 100mcg/hr trans pad, Ran Fentanyl 2.5mg, 5mg, 7.5mg 10mg trans pad, Duragesic 12 1.25mg trans pad, Ratio Fentanyl 4.125mg, 16.5mg, 8.25mg, 12.375mg trans pd, Risperdal Consta 25mg/vial, 37.5mg/vial, 50mg/vial, Revised Criteria: Fosamax 10mg, 70mg tab, Novo Alendronate 10mg, 70mg tab, Apo Alendronate 10mg, 70mg tab, Co Alendronate 70mg tab, Gen Alendronate 10mg, 70mg tab, Pms Alendronate 70mg tab, Ratio Alendronate 70mg tab, Sandoz Alendronate 10mg, 70mg tab, Actonel 5mg, 35mg tab, Evista 60mg tab, Miacalcin 200u nas sol.
Posted May 15, 2008
Newfoundland
Newfoundland Bulletin No. 15 - May 12, 2008
Highlights
Highlights to follow shortly.
Posted May 8, 2008
Ontario
ODB Edition 40, Update 12, effective May 15, 2008
Highlights
New Single Source Drug(s): Dovobet 50mcg/g & 0.5mg/g Oint; Apo-Pantoprazole 40mg Tab Ent; Novo-Enalapril 2.5mg, 5mg, 10mg, 20mg Tab; PMS-Clindamycin 150mg Cap. Discontinued by Manufacturer: Apo-Cromolyn 1% Inh Sol-2ml Pk; Novo-Cyproterone 50mg Tab. Price Changes: MetroLotion 0.75% Top Lot; Phenobarbital 120mg/ml Inj Sol-1ml Pk. Not-A-Benefit Drug(s): Diflucan 50mg, 100mg Tab; Halcion 0.25mg Tab; Norpace 100mg, 150mg Cap. Off Formulary Interchangeable Product(s): Novo-Clonidine 0.025mg Tab. Discontinued Drug(s): Gabapentin 300mg Cap; Hepalean 25000USP U/ml Inj Sol-2ml Pk; Nipride Inj Pd-50mg Pk; Novo-Misoprostol 200mcg Tab; Novo-Naprox 750mg SR Tab; Ratio-Ipratropium 0.03% Nasal Spray; Ratio-Nystatin 100000U Vag Tab; Sandoz Risperidone 0.25mg Tab; Trasicor 80mg Tab; Triphasil 3 Phase Tab-21Pk, 28Pk.
Posted May 7, 2008
New Brunswick
NB Benefit Changes to NBPDP, Bulletin #715, May 7, 2008
Highlights
Special Authorization Additions: Humira 40mg in 0.8ml (50mg/ml) sol, Baraclude 0.5mg tab, Biphentin 10mg, 15mg, 20mg, 30mg, 40mg, 50mg, 60mg cap, Tracleer 62.5mg, 125mg tab; Special Authorization – Revised Criteria: Plavix 75mg tab; Drugs Reviewed and Not Listed: Elaprase 6mg vial, Concerta 18mg, 27mg, 36mg, 54mg tab CR
Posted May 5, 2008
Prince Edward Island
MAC Memo, May 5, 2008
Highlights
New Interchangeable/Mac Cateories: Didrocal 400mg & 500mg Tab Pk; Co Etidrocal 400mg & 500mg Tab Pk. Products Added to the Interchangeable/Mac List: Novo-Pantoprazole 20mg, 40mg Tab Ent; PMS-Morphine Sulfate SR 100mg, 200mg Tab SR; PMS-Olanzapine 2.5mg, 5mg, 7.5mg, 10mg, 15mg Tab. Changes to MAC Prices: Ratio-Lenoltec No. 3 30mg Tab; Tylenol No.3 30mg Tab; Combivent 1.0mg/ml & 0.2mg/ml Inh Sol; Ratio-Ipra Sal UDV 1.0mg/ml & 0.2mg/ml Inh Sol; Apo-Salvent Ipravent 1.0mg/ml & 0.2mg/ml Inh Sol; Gen-Combo Sterinebs 1.0mg/ml & 0.2mg/ml Inh Sol; Pred-Forte 1% Oph Susp; Ratio-Prednisolone 1% Oph Susp; Sandoz Prednisolone 1% Oph Susp. Deleted Interchangeable/MAC Categories: Ditropan 1mg/ml Syrup; Pms-Oxybutynin 1mg/ml Syrup; Apo-Oxybutynin 1mg/ml Syrup. Discontinued Products: Apo-Cromolyn 1% Inh Neb Sol. Status Change: Amatine 2.5mg, 5mg Tab; Apo-Midodrine 2.5mg, 5mg Tab.
Posted May 5, 2008
Alberta
Additions to the AHWDBL, effective May 1, 2008
Highlights
New Interchangeable Products: gen clarithromycin 500mg tab, pms clarithromycin 500mg tab, ratio clarithromycin 500mg tab, biaxin bid 500mg tab, ran pantoprazole 40mg EC tab, pantoloc 40mg EC tab, novo morphine SR 100mg, 200mg tab, ms contin 100mg, 200mg tab. New Single Source Products: Altace HCT 2.5mg/12.5mg, 5mg/12.5mg, 5mg/25mg, 10mg/12.5mg, 10mg/25mg tab.
Posted May 5, 2008
Alberta
Additions by Special Authority to AEIDBS
Highlights
New Products Available by Special Authorization: Neocate Oral Infant Formula, Nutramigen Oral Infant Formula, Similac Alimentum with Iron Oral Infant Formula.
Posted April 29, 2008
Nova Scotia
Nova Scotia Pharmacare Bulletin Vol #08-04, April 2008
Highlights
New Products: Medlance Plus Extra 200's 21G, 2.4mm, Medlance Plus Universal 200's 21G, 1.8mm, Medlance Plus Lite 200's 25G 1.5mm, sandoz lisinopril HCT 10mg/12.5mg, 20mg/12.5mg, 20mg/25mg tab; New Interchangeable Products: novo atenolthalidone 50mg&25mg tab, 100mg&25mg tab, apo bicalutamide 50mg tab, pms bisoprolol 5mg, 10mg tab, sandoz brimonidine 0.2% oph sol, sandoz cefprozil 112mg/5ml, 250mg/5ml o/l, sandoz cefprozil 250mg, 500mg tab, novo citalopram 40mg tab, pms clindamycin 150mg cap, 300mg cap, pms enalapril 2.5mg, 5mg, 10mg, 20mg tab, taro enalapril 2.5mg, 5mg, 10mg, 20mg tab, fenomax 160mg cap, co fluconazole 50mg, 100mg tab, pms gliclazide 80mg tab, pms ISMN SR 60mg SR tab, apo lisinopril/HCTZ 10mg&12.5mg tab, gen lisinopril/HCTZ 10mg&12.5mg tab, novo lisinopril/HCTZ (type p) 10mg&12.5mg tab, novo lisinopril/HCTZ (type z) 10mg&12.5mg tab, prinzide 10mg&12.5mg tab, zestoretic 10mg&12.5mg tab, pms minocycline 50mg, 100mg cap, novo morphine SR 60mg SR tab, gen pravastatin 10mg, 20mg, 40mg tab, ran rabeprazole 10mg, 20mg EC tab, co ramipril 1.25mg, 2.5mg, 5mg, 10mg cap, ramipril 2.5mg, 5mg, 10mg cap, ran tamsulosin 0.4mg SR cap, pms temazepam 15mg, 30mg cap, co venlafaxine XR 37.5mg, 75mg, 150mg XR cap, pms venlafaxine XR 37.5mg, 75mg, 150mg XR cap.
Posted April 29, 2008
Québec
Quebec Capsule, effective April 21, 2008
Highlights
Addition of Exception Medication: Isentress 400mg Tab
Posted April 22, 2008
Manitoba
Manitoba Bulletin #58, effective April 29, 2008
Highlights
Additions: Apo Clozapine 25mg, 100mg tab, Co Venlafaxine XR 37.5mg, 75mg, 150mg cap, CTP 30mg tab, Gen Atenolol 25mg tab, Gen Clozapine 50mg, 200mg tab, Gen Metoprolol (type L) 25mg tab, Novo morphine SR 60mg tab, pms Amiodarone 100mg tab, pms bisoprolol 5mg, 10mg tab, pms clindamycin 150mg, 300mg tab, pms doxycycline 100mg tab, 100mg cap, pms enalapril 2.5mg, 5mg, 10mg, 20mg tab, pms gliclazide 80mg tab, pms lisinopril 5mg, 10mg, 20mg tab, pms paroxetine 40mg tab, pms venlafaxine XR 37.5mg, 75mg, 150mg cap, ratio enalapril 2.5mg, 5mg, 10mg, 20mg tab, ratio lisinopril P 5mg, 10mg, 20mg tab, ratio lisinopril Z 5mg, 10mg, 20mg tab, ratio ramipril 1.25mg, 2.5mg, 5mg, 10mg cap, ratio tamsulosin 0.4mg cap, ratio venlafaxine XR 37.5mg, 75mg, 150mg cap, sandoz brimonidine 0.2% oph sol, sandoz enalapril 2.5mg, 5mg, 10mg, 20mg tab, sandoz lisinopril 5mg, 10mg, 20mg tab, sandoz lisinopril HCT 10/12.5mg, 20/12.5mg, 20/25mg tab, sandoz ramipril 1.25mg, 2.5mg, 5mg, 10mg cap, sandoz risperidone 0.25mg tab, sandoz tamsulosin 0.4mg cap, co fluconazole 50mg, 100mg tab, pms minocycline 50mg, 100mg cap, ran ciproflox 250mg, 500mg, 750mg tab, sandoz cefprozil 250mg, 500mg tab, sandoz cefprozil 125mg/5ml, 250mg/5ml susp, co pioglitazone 15mg, 30mg, 45mg tab, pms ISMN 60mg tab, pms levetiracetam 250mg, 500mg, 750mg tab, pms naproxen EC 375mg, 500mg tab, pms pioglitazone 15mg, 30mg, 45mg tab, ratio omeprazole 20mg tab, ratio pioglitazone 15mg, 30mg, 45mg tab, sandoz omperazole 20mg cap, sandoz pioglitazone 15mg, 30mg, 45mg tab, sutent 12.5mg, 25mg, 50mg cap, nexavar 200mg tab. New Interchangeable Products: 89, see bulletin for list. Interchangeable Product Price Changes: ratio oxycocet 5/325mg tab, ratio lenoltec No.2 300/15/15mg tab, ratio lenoltec No.3 300/15/30mg tab, ratio lenoltec No.4 300/60mg tab.
Posted April 17, 2008
Newfoundland
Newfoundland and Labrador Bulletin No 13 April 16, 2008
Highlights
92 additions - See bulletin for details.
Posted April 17, 2008
Newfoundland
Newfoundland and Labrador Bulletin No 12 April 15, 2008
Highlights
107 new interchangeable products - See buletin for details.
Posted April 15, 2008
Newfoundland
Newfoundland and Labrador Bulletin No 10 March 29, 2008
Highlights
The following DINs are Open Benefit to All Plans under NLPDP and Speacial Authorization for Cystics effective April 1, 2008: Apo Glimepiride 1mg, 2mg 4mg Tablet, Co Glimepiride 1mg, 2mg, 4mg Tablet, Novo Glimepiride 1mg, 2mg, 4mg Tablet, ratio Glimepiride 1mg, 2mg, 4mg Tablet, Sandoz Glimepiride 1mg, 2mg, 4mg Tablet
Posted April 1, 2008
Alberta
Summary of Changes to the Alberta Health and Wellness Drug Benefit List - April 1, 2008
Highlights
New Drug Products Available by Special Authorization effective April 1, 2008: Baraclude 0.5mg tab, Hepsera 10mg tab; Additional Brands and/or Strengths of Drug Products Available by Special Authorization: Co Cabergoline 0.5mg tab, Pipercillin Sodium/Tazobactam Sodium 2g/vial (base) 250mg/vial base injection, Pipercillin Sodium/Tazobactam Sodium 3g/vial (base) 375mg/vial (base) injection, Pipercillin Sodium/Tazobactam Sodium 4g/vial (base) 500mg/vial (base) injection; Drug Products with Changes to Criteria for Coverage: Pegasys 180mcg/ml injection, Pegasys (0.5m; syringe) 180mgc/syr injection syringe; Discontinued Special Authorization Drug Products: Panoxyl 15 topical (alcohol) gel, Retin-A 0.01%, 0.025% topical cream, Vitamin A Acid 0.01%, 0.025%, 0.05%, 0.1% topical cream; Additional Brands and/or Strengths of Drug Products Available by Optional Special Authorization: Leavquin 750mg tab; Added Products: Apo Amoxi Clav 80mg/11.4ml oral susp, Apo Lisinopril/HCTZ 10mg/12.5mg tab, Aviane 21 tab, Avaine 28 tab, Ciprodex 0.3%/0.1% otic susp, Co Ramipril 1.25mg, 2.5mg, 5mg, 10mg cap, CTP 30mg tab, Hyzaar 100mg/12.5mg tab, Novo Citalopram 20mg tab, Novo Enalapril 2.5mg, 5mg, 10mg, 20mg tab, Novo Enalapril/HCTZ 5mg/12.5mg, 10mg/25mg tab, Novo Rabeprazole 10mg, 20mg enteric coated tab, Pms ISMN 60mg ER tab, Pms Venlafaxine XR 37.5mg, 75mg, 150mg ER tab, Sandoz Omeprazole 10mg, 20mg SR cap, Taro Enalapril 2.5mg, 5mg, 10mg, 20mg tab; Change in Status from Special Authorization to Unrestricted: Losec 10mg SR tab; Deleted Products: 56 products listed. See list for details.
Posted April 1, 2008
Saskatchewan
Formulary & EDS Updates Bulletin # 114
Highlights
Effective April 1, 2008 the following products will be listed as benefits: gen Atenolol 25mg Tab, sandoz Brimonidine 0.2% oph sol, Sandoz Cefprozil 25mg/ml, 50mg/ml o/susp, mint Citalopram 20mg, 40mg Tab, pms Clindamycin 150mg, 300mg Cap, Aviane 21 & Aviane 28 0.02mg/0.1mg tab, pms ISMN 60mg Tab, gen Metoprolol 25mg tab, pms Minocycline 50mg, 100mg Cap, novo Morphine SR 60mg, 100mg, 200mg tab ER, apo pantoprazole 40mg tab, ran pantoprazole 40mg tab, apo timop gel 0.5mg oph gel sol; Exception Drug Status Criteria Effective April 1, 2008: Sandoz Cefprozil 25mg/ml, 50mg/ml o/susp, pms Minocycline 50mg, 100mg cap, apo Pantoprazole 40mg tab, ran Pantoprazole 40mg tab; Effective April 1, 2008 the EDS Criteria has been approved for a new indication: Humira 40mg/0.8ml pre filled syringe; Effective April 1, 2008the EDS Criteria for the following products have been revised as indicated: Axert 6.25mg, 12.5mg tab, Amerge 1mg, 2.5mg tab, Maxalt 5mg, 10mg tab, Maxalt 5mg, 10mg wafer, Imitrex25mg, 50mg, 100mg tab, Imitrex 6mg/0.5ml inj sol, Imitrex 5mg, 20mg nasal spray, Zomig 2.5mg tab, Zomig 2.5mg o/dis tab, DDAVP-FEI 10mcg/dose, apo Desmopressin 10mcg/dose, Ketek 400mg tab; Price Changes: Suprax 400mg tab, Losec 20mg tab/cap, apo omeprazole 20mg tab/cap.
Posted March 26, 2008
British Columbia
BC Pharmacare Newsletter Edition 08-003
Highlights
Extended Coverage of Drug Treatments for Chronic Hepatitis B effective March 27, 2008: Extended PharmaCare Special Authority coverage for Heptovir and Intron A, New Special Authority coverage for Hepsera and Baraclude
Posted March 31, 2008
Ontario
ODB Update 11, effective April 9 2008
Highlights
New Multi Source Drugs: Co Venlafaxine 37.5mg, 75mg, 150mg Cap ER, Novo Morphine SR 60mg, 100mg, 200mg Tab ER, pms Clindamycin 300mg Cap, pms Propafenone 150mg, 300mg Tab, ran Pantoprazole 40mg Ent Tab, Sandoz Rampril 1.25mg, 2.5mg, 5mg, 10mg Tab; Manufacturer Requested Discontinued Drug(s): Kwellada-P 1% Cr Rinse, Kwellada-P 5% Lot, Nix Dermal Cream 5% Cr, Panoxyl 15% Gel, R&C Shampoo/Conditioner 0.3% & 3% & 1.2% Top Sol, Trasicor 40mg Tab; New Diabetic Testing Agents: Ascensia Breeze 2 Strip; Not-A-Benefit Drug(s): apo Amoxi Clav 400mg & 57mg/ml Susp, gen Domperidone 10mg Tab; Off Formulary Interchangeable Products: gen Metformin 850mg Tab, pms Metformin 850mg Tab, pms Minocycline 50mg, 100mg Cap, ran Metformin 850mg Tab; Drug Benefit Price(s): 325 See List for Details
Posted March 31, 2008
Saskatchewan
Saskatchewan Bulletin #114, April 2008
Highlights
New Full Formulary Interchangeable Listings: gen Atenol 25mg Tab, Aviane 21 & Aviane 28 0.02mg/0.1mg Tab, gen Metoprolol 25mg Tab; Revised Exception Drug Status (EDS) Criteria: New Safety Information: apo Desmopressin intranasal solution, Health Canada Alert: Ketek 400mg Tab. Axert 6.25mg, 12.5mg Tab, Amerge 1mg, 2.5mg Tab, Maxalt 5mg, 10mg Tab, Maxalt 5mg, 10mg wafer, Imitrex 25mg, 50mg 100mg Tab, Imitrex 6mg/0.5ml inj sol, imitrex 5mg, 20mg nasal spray, Zomig 2.5mg Tab, Zomig 2.5mg o/dis Tab; Exception Drug Status (EDS) Drugs Approved for a New Indication: Humira 40mg/0.8ml pre filled syringe; Products Not Recommended by the Saskatchewan Review Committees: Cyestra 0.035mg/2mg Tab (21 Tab), Elaprase 2mg/ml inj sol, Thelin 100mg Tab, Fosrenol 250mg, 500mg, 750mg, 1000mg Tab, Spriafil 40mg/ml o/susp, Mezavant 1.2g ER Tab, CTP-30 30mg Tab; New Interchangeable Listings Effective April 1, 2008: Sandoz Brimonidine 0.2% oph sol, mint Citalopram 20mg, 40mg Tab, pms Clindamycin 150mg, 300mg Tab, pms ISMN 60mg Tab, novo Morphine SR 60mg, 100mg, 200mg ER Tab, apo Timop 0.5% oph gel; 2008 According to Current EDS Criteria: Sandoz Cefprozil 25mg/ml, 50mg/ml o/susp, pms Minocycline 50mg, 100mg Cap, apo pantoprazole 40mg Tab, ran Pantoprazole 40mg Tab
Posted March 31, 2008
New Brunswick
Benefit Changes to NBPDP, Bulletin 711, March 27, 2008
Highlights
Regular Benefit Additions: Linessa 21 & Linessa 28 100/125/150/25mcg Tab, Rebif Initiation Pack 8.8mcg/0.2ml & 22mcg/0.5ml INJ-SC SOL, Altace 15mg Cap; No longer requires Special Authorization: Lamictal Chewtabs 2mg, 5mg Tab Chew, Lamictal 25mg, 100mg, 150mg Tab, apo Lamotrigine 25mg, 100mg, 150mg Tab, gen Lamotrigine 25mg, 100mg, 150mg Tab, novo Lamotrigine 25mg, 100mg, 150mg Tab, pms Lamotrigine 25mg, 100mg, 150mg Tab, ratio Lamotrigine 25mg, 100mg, 150mg Tab; Special Authorization Addisions: Hepsera 10mg Tab, Ciprodex 0.3%/0.1% otic susp, Duragesic 12mcg/h transdermal patch, Pegasys 180mcg/1ml vial & 180mcg/1ml prefilled syringe; Drugs Reviewed and Not Listed: Sativex 27mg/ml/ 25mg/ml buccal spray, Trusopt 2% preservative free oph sol, Cosopt 2%/0.5% preservative free oph sol, Pegasys 180mcg/1ml vial & 180mcg/1ml prefilled syringe, Sebivo 600mg Tab, Zytram XL 150mg, 200mg, 300mg, 400mg controlled release Tab.
Posted March 28, 2008
Newfoundland
Newfoundland Bulletin No 8, correction to Bulletin #6
Highlights
Delisted from the NIDPF and as a benefit of NLPDP effective March 26, 2008 not delisted as a benefit of NLPDP effective April 1, 2008 as indictaed in Bulletin #6: Ratio-Fluticasone 50mcg/metered Dose Nasal Spray.
Posted March 28, 2008
Newfoundland
Newfoundland Bulletin No 7 , effective March 26, 2008
Highlights
Delisted from the NIDPF effective March 26, 2008: ratio-Fluticasone Aqueous Spray, Flonase Aqueous Spray
Posted March 28, 2008
Newfoundland
Newfoundland Bulletin No 6, March 12, 2008
Highlights
NLPDP Product Deletion: Ratio-Flicasone 50mcg/metered dose nasal spray
Posted March 25, 2008
British Columbia
BC Pharmacare Newsletter Edition 08-002, Mar 20, 2008
Highlights
Now Available as Limited Coverage Drugs through the PharmaCare Special Authority Program: Adalimumab 40mg/0.8ml Inj; Etanercept 25mg/vial, 50mg/ml Inj; Infliximab 100mg/vial IV.
Posted March 25, 2008
New Brunswick
Formulary Product Updates, Vol 49, Update No.#3 Mar 4, 2008
Highlights
Addition to New Brunswick Formulary: Gen-Atenolol 25mg Tab; Novo-Atenolthalidone 50mg/25mg, 100mg/25mg Tab; Apo-Bialutamide 50mg Tab; Gen-Biclutamide 50mg Tab; pms-Bisoprolol 5mg, 10mg Tab; Novo-Citalopram 40mg Tab; pms-Clindamycin 150mg, 300mg Cap; Vaseretic 5mg/12.5mg, 10mg/25mg Tab; Novo-Enalapril/HCTZ 5mg/12.5mg, 10mg/25mg Tab; Co-Fluconazole 50mg, 100mg Tab; pms-Gliclazide 80mg Tab; pms-ISMN 60mg Tab; Prinzide 10mg/12.5mg, 20mg/12.5mg, 20mg/25mg Tab; Zestoretic 10mg/12.5mg, 20mg/12.5mg, 20mg/25mg Tab; Novo-Lisinopril HCTZ (Type P) 10mg/12.5mg, 20mg/12.5mg, 20mg/25mg Tab; Novo-Lisinopril (Type Z) 10mg/12.5mg, 20mg/12.5mg, 20mg/25mg Tab; Apo-Metoprolol 25mg Tab; Gen-Metoprolol (Type L) 25mg Tab; pms-Minocycline 50mg, 100mg Cap; Co-Pioglitazone 15mg, 30mg, 45mg Tab; pms-Pioglitazone 15mg, 30mg, 45mg Tab; Co-Ramipril 1.25mg, 2.5mg, 5mg, 10mg Cap; pms-Temazepam 15mg, 30mg Cap; pms-Venlafaxine XR 37.5mg, 75mg, 150mg Cap. New Interchangeables: Novo-Enalapril/HCTZ 5mg/12.5mg, 10mg/25mg Tab; Apo-Metoprolol 25mg Tab; Gen-Metoprolol (Type L) 25mg Tab.
Posted March 25, 2008
New Brunswick
Benefit Changes to NBPDP, Bulletin #710, Mar 4, 2008
Highlights
NBPDP Benefit Additions: Gen-Atenolol 25mg Tab; Novo-Atenolthalidone 50mg/25mg, 100mg/25mg Tab; Apo-Bialutamide 50mg Tab; Gen-Biclutamide 50mg Tab; pms-Bisoprolol 5mg, 10mg Tab; Novo-Citalopram 40mg Tab; pms-Clindamycin 150mg Cap; Novo-Enalapril/HCTZ 5mg/12.5mg, 10mg/25mg Tab; Co-Fluconazole 50mg, 100mg Tab; pms-Gliclazide 80mg Tab; pms-ISMN 60mg Tab; Novo-Lisinopril HCTZ (Type P) 10mg/12.5mg, 20mg/12.5mg, 20mg/25mg Tab; Novo-Lisinopril (Type Z) 10mg/12.5mg, 20mg/12.5mg, 20mg/25mg Tab; Gen-Metoprolol (Type L) 25mg Tab; pms-Minocycline 50mg, 100mg Cap; Co-Pioglitazone 15mg, 30mg, 45mg Tab; pms-Pioglitazone 15mg, 30mg, 45mg Tab; Co-Ramipril 1.25mg, 2.5mg, 5mg, 10mg Cap; pms-Temazepam 15mg, 30mg Cap; pms-Venlafaxine XR 37.5mg, 75mg, 150mg Cap. Non-Listed Products Subject to Map: pms-Clindamycin 300mg Cap.
Posted March 20, 2008
Nova Scotia
NS Pharmacare Bulletin Vol #08-03, March 2008
Highlights
New Pharmacare Reimbursement Levels effective March 15, 2008: ratio Oxycocet 5mg Tab, Life Brand Portable System (50), Life Brand Test Strips 50, 100; Change in Criteria: Zyprexa Zydis; New Products: Cuprimine 205mg Cap, pms Amiodarone 100mg Tab, pms Hydrochlorothiazide 12.5mg Tab, pms Paroxtine 40mg Tab, Reyataz 300mg Cap; New Diabetic Products: FreeStyle Lite Test Strips 50/box, 100/box; Additions to Exception Status for Selected Anti Tumor Necrosis Factor (TNF) Agents: Remicade, Humira, Enbrel
Posted March 20, 2008
Ontario
ODB Update 10 - Second Amendment, effective Mar 25, 2008
Highlights
Not a Benefit Drug: Apo-Perindopril 8mg Tab
Posted March 19, 2008
Ontario
ODB Update 10 - Amended, effective Mar 25, 2008
Highlights
Not a Benefit Drugs: Sandoz-Diclofenac SR 75mg, 100mg LA Tab
Posted March 13, 2008
Ontario
ODB Update 10, effective Mar 25, 2008
Highlights
New Single Source Drug(s): Lucentis 10mg/ml Inj Sol-0.3mL Vial Pk; New Multi Source Drug(s): Ceftriaxone Sodium for Injection 1g/vial, Gen Bicalutamide 50mg, Octreotide Acetate Omega 50mcg/ml, 100mcg/ml, 200mcg/ml Inj Sol- 1ml Amp Pk, Octreotide Acetate Omega 500mcg/mL Inj Sol- 5mL Vial pk, Pms Temazepam 15mg, 30mg Cap, Ran Ciproflox 250mg, 500mg, 750mg Tab, Sandoz Cefprozil 250mg, 500mg Tab, Sandoz Diclofenac SR 75mg, 100mg LA Tab; Manufacturer Requested Discontinued Drugs: Gen Clomipramine 10mg, 25mg, 50mg Tab, Gen Diltiazem 30mg, 60mg Tab, Peg Lyte Sol- 1L pk, Pms Cholestyramine Oral Pd 42 Dose Pk, Pms Cholestyramine (sugar free) Oral Pd 42 Dose Pk, Pms Ketoprofen E-50 50mg Ent Tab, Pms Loxapine 25mg/ml O/L, Pms Oxtriphylline 10mg/ml O/L, PMS Temazepam 15mg, 30mg Cap, PMS Theophylline 5.3mg/ml O/L; Price Change- Drug Benefit Price: Ratio-Oxycocet 5mg, 325mg Tab; New Manufacturer Name: Resultz 50% Top Sol 120ml Pk, Resultz 50% Top Sol 240ml Pk; Off Formulary Interchangeable Products: Apo Alpraz 1mg Tab, Apo Alpraz TS 2mg Tab, Gen Alprazolam 1mg, 2mg Tab, Pms Pamidronate 3mg/ml, 9mg/ml Inj Sol- 10ml Vial; Discontinued Drugs Removed from Payment and Listing: Megacillin 500 500000IU Tab, Pms Cimetidine 200mg, 300mg, 400mg, 600mg, 800mg Tab, PMS Dexamethasone 0.1% Oph/Ot Sol, Pms Gentamicin 0.3% Oph Sol, Pms Ketoprofen 50mg Cap, Pms Ketoprofen E-100 100mg Ent Tab, Pms Metoprolol-B 50mg, 100mg Tab, Pms Misoprostol 200mcg Tab, Pms Nifedipine 5mg, 10mg Cap, Pms Piroxicam 10mg, 20mg Cap, Pms Piroxicam 10mg Sup, Pms Tiaprofenic 200mg Tab, Pms Trihexyphenidyl 0.4mg/ml O/L
Posted March 10, 2008
Prince Edward Island
PEI Formulary Update Issue 08-01, Mar 3, 2008
Highlights
Additions to the Drug Programs Formulary effective immediately: 59 listed. See Update for details. Status Change to Full Benefit: 46 listed. See Update for details. Changes to Criteria: 115 listed. See Update for details.
Posted March 10, 2008
Quebec
Modification no 1, correction no4, effective Feb 22, 2008
Highlights
Additions: Apo-Pioglitazone 15mg, 30mg, 45mg Tab; Co Pioglitazone 15mg, 30mg, 45mg Tab; Gen-Pioglitazone 15mg, 30mg, 45mg Tab, Novo-Pioglitazone 15mg, 30mg, 45mg Tab; pms_Pioglitazone 15mg, 30mg, 45mg Tab; ratio-Pioglitazone 15mg, 30mg, 45mg Tab; Sandoz Pioglitazone 15mg, 30mg, 45mg Tab. Price changes: 49 products affected - see update for details. Discontinued at request of manufacturer: Novo-Ramipril 1.25mg Cap or Tab
Posted March 3, 2008
Manitoba
Manitoba Drug Benefits and Interchangeability Formulary Amendments, Bulletin #57 effective Mar 19, 2008
Highlights
Additions: 126 new additions- See List for Details; New Interchangeable Categories: 102 new interchangeable categories- See List for Details; New Interchangeable Products: 55 new interchangeable products- See List for Details; Product Deletions: 55 product deletions- See List for Details; Category Changes: Novo Mirtazapine OD 15mg, 30mg, 45mg Tab; Interchangeable Product Price Changes: 62 interchangeable product price changes- See List for Details; Discontinued Products: 50 discontinued products- See List for Details
Posted February 20, 2008
Saskatchewan
Saskatchewan Bulletin #113, February 2008
Highlights
New Formulary Listing: Life Brand Blood Glucose Monitoring Test Strips- HOM, Losartan potassium/HCTZ 100mg/12.5mg Tab (Hyzaar MSD); Exception Drug Status- Drugs Approved for New Indication: Adalimumab pre filled syringe 40mg/0.8ml (Humira ABB), Etanercept powder for injection (vial) 25mg/vial; pre filled syringe, 50mg/ml (Enbrel- AMG); New Exception Drug Status: Adefovir dipivoxil 10mg Tab (Hepsera-GSI), Alglucosidase alfa, powder for solution, 50mg/vial (Myozyme-GZY), Ciprofloxacin HCl/dexamethasone, otic suspension, 0.3%/0.1% (Ciprodex-ALC), Entecavir 0.5mg Tab (Baraclude-BMY); New Strength/Dosage Forms: Adalimumab, pre filled syringe 40mg/0.8ml (Humira Pen- ABB), Darbepoetin alfa 500ug/ml pre filled syringe (Aranesp-AMG), Desmopressin 50ug, 120ug Tab (DDAVP Melt-FEI), Risedronate sodium 75mg Tab (Actonel-PGA); Revised EDS Criteria: Insulin Aspart, injection for solution, 100U/ml (5x3ml), 10ml , Novo Rapid-NOO, Insulin Lispro, injection for solution 100U/ml 5x1.5ml, 5x3ml Humalog- LIL, Levofloxacin 250mg, 500mg Tab (Levaquin-JAN); Under Review with the National Common Drug Review: Aclasta (osteoporosis), Adderall XR, Atripla, Invega, Isentress, Januvia, Lucentis, Ralivia, Rasilez, Tridural, Zeldox; Under Review by the Saskatchewan Review Committees: Sativex, Raptiva, Enbrel, Remicade; Products not Recommended for Coverage via the Common Drug Review Process: Natalizumab 300mg/ml inj sol (tysabri-BGN), Delta-9-Tetrahydrocannabinol and cannabidiol 27mg/ml & 25mg/ml buccal spray, Tramadol Hydrochloride 150mg, 200mg, 300mg, 400mg Tab (Zytram-XL-PFR), Telbivudine 600mg Tab (Sebivo-NVR), Varenicline 0.5mg, 1mg Tab (Champix-PFI); Products not Recommended by the Saskatchewan Review Committees: Infliximab 100mg/vial injection (Remicade-SCH), Amiodarone 100mg Tab (Pms Amiodarone-PMS), Paroxetine HCl 40mg Tab (pms-Paroxetine- PMS), Methylphenidate HCl 80mg Cap (Biphentin PFR), Testosterone 1% gel for transdermal application (Testim-PAL); New Interchangeable Listings effective 11/01/2007: Citalopram hydrobromide 20mg Tab (novo Citalopram- NOP), Enalapril 2.5mg, 5mg, 10mg, 20mg Tab (Apo Enalapril- APX) (Co Enalapril- COB), (Gen Enalapril-GPM), (Novo Enalapril- NOP), (Pms Enalapril-PMS), (Ratio Enalapril-RPH), (Sandoz Enalapril-SDZ), Ethinyl Estradiol/1-Norgestrel 0.03mg/0.15mg Tab (21 tablet) (28 tablet) (Portia-APX), Lisinopril 5mg, 10mg, 20mg Tab (Apo Lisinopril- APX), (Co Lisinopril-COB), (Gen Lisinopril- GPM), Novo Lisinopril-NOP), (pms-Lisinopril-PMS), (Ran-Lisinopril-RAN), (Ratio Lisinopril-RAN), (Sandoz-Lisinopril-SDZ), Lisinopril/Hydrochlorothiazide 10mg/12.5mg Tab (Apo Lisinopril/HCTZ-APX), Ramipril 1.25mg, 2.5mg, 5mg, 10mg Tab (Sandoz Ramipril-SDZ) 1.25mg, 2.5mg, 5mg, 10mg Cap (Co Ramipril-COB), Tamsulosin HCl 0.4mg SR Cao (Ran Tamsulosin-RAN), Venlafaxune HCl 37.5mg, 75mg, 150mg Cap (Pms Venlafaxine XR-PMS); New Interchangeable EDS Listings effective 11/01/2007: Amoxicillin trihydrate/potassium clavulanate 80mg/11.4mg/ml oral suspension (Apo Amoxi Clav- APX), Omeprazole 10mg, 20mg Cap (Sandoz Omeprazole-SDZ); New Interchangeable Listings effective 12/01/2007: Enalapril 2.5mg, 5mg, 10mg, 20mg Tab (Taro Enalapril-TAR), Lisinopril/HCTZ 10mh/12.5mg Tab (Gen Listinopril/HCTZ-GPM), (Novo Listinopril/HCTZ-NOP), Sandoz Listinopril/HCTZ-SDZ), Listinopril/HCTZ 20mg/12.5mg Tab, (Apo Listinopril/HCTZ-APX), (Gen Listinopril/HCTZ- GPM), Novo Listinopril/HCTZ-NOP), (Sandoz Listinopril/HCTZ-SDZ), Listinopril/HCTZ 20mg/25mg Tab, (Apo Listinopril/HCTZ-APX), (Gen Listinopril/HCTZ-GPM), (Novo Listinopril/HCTZ-NOP), Sandoz Listinopril/HCTZ-SDZ); New Interchangeable EDS Listings effective 12/01/2007: Cabergoline 0.5mg Tab (Co Cabergoline-COB), Omeprazole 20mg Cap (Losec-AST), Rabeprazole Sodium 10mg, 20mg Tab (Novo Rabeprazole-NOP), (Ran Rabeprazole-RAN); New Interchangeable EDS Listings effective 02/15/2008: Atenol/chlorthalidone 50mg/25mg, 100mg/25mg Tab (Novo Atenolthalidone-NOP), Citalopram hydrobromide 40mg Tab (Novo-Citalopram-NOP), Htdromorphone HCl 3mg sup (Pms Hydromorphone-PMS), Temazepam 15mg, 30mg Cap (Pms Temazepam-PMS); New Interchangeable EDS Listings effective 02/15/2008: Bisprolol fumarate 50mg, 10mg Tab (Pms Bisoprolol-PMS), Cefprozil 250mg, 500mg Tab (Sandoz Cefprozil-SDZ), Piogliazone 15mg, 30mg, 45mg Tab (Gen Piogliazone-GPM), Apo Piogliazone-APX), (Co Piogliazone-COB), (Novo Piogliazone-NOP), (Ratio Piogliazone-RPH), (Sandoz Piogliazone-SDZ), (Pms Piogliazone-PMS); Product(s) withdrawn from the Market by Health Canada: Pergolide mesylate 0505mg, 0.25mg, 1mg Tab (Permax-RBP).
Posted February 20, 2008
British Columbia
BC Pharmacare Newsletter Edition 08-001, Feb 18, 2008
Highlights
Extension of Coverage Period for Plavix; New Drugs Categorized to LCA and/or RDP: Co Rampril 10mg, 5mg, 2.5mg, 1.25mg Cap, Co Topiramate 200mg, 100mg, 25mg Tab, Pms Clarithromycin 500mg, 250mg Tab, Pms Digoxin 0.0625mg Tab, Pms Venlafaxine XR 150mg, 75mg, 37.5mg Caps, Ratio Venlafaxine 150mg, 75mg, 37.5mg Caps, Pms Fluconazole 150mg Caps; New Drugs Categorized to LCA by Exception: Pms Paroxetine (Paroxetine) 40mg Tab; Benefits: Alvesco (Ciclesonide) 100mcg, 200mcg inhaled dose, Duotrav (Travoprost and Timolol Maleate) 0.004%/0.5% ophthalmic solution, Pms Amiodarine 100mcg Tab, Hypertonic Saline Compound Solution, Sodium Chloride 14.6 mg/ml injection, Sodium Chloride for injection 23.4%, Sterile water for injection; Limited Coverage Program: Nutropin (Somatropin) 5mg/vial, 10mg/vial, Nutropin AQ (Somatropin) 10mg/2ml vial, Nutropin AQ Pen (Somatropin) 10mg/2ml cartridge; Non Benefits: Apo Glimepiride 4,g, 2mg, 1mg Tab, Nutropin (Somatropin) 5mg/vial, 10mg/vial, Nutropin AQ (Somatropin) 10mg/2ml vial, Nutropin AQ Pen (Somatropin) 10mg/2ml cartridge; Submission Withdrawn: Actonel Plus Calcium 35mg-500mg Tab
Posted February 12, 2008
Newfoundland
Behind the Scenes - Winter 2007
Highlights
Newfoundland and Labrador Prescription Drug Program Changes; Newfoundland and Labrador Interchangeable Formulary: New Categories Effective January 1, 2008 to Interchangeable Formulary: Benazepril Hydrochloride 5mg and 10mg Tabs, Olanzapine 2.5mg, 5mg, 7.5mg, 10mg, and 15mg Tabs, Cefprozil 250mg and 500mg Tabs, Cefprozil 125mg/5ml and 250mg/5ml suspension, Levonorgestrel/Ethinyl Estradiol 0.15mg/0.03mg Tabs, Fluticasone Propionate 50mcg/metered dose spray, Enalapril Maleate 2.5mg, 5mg, 10mg, and 20mg Tabs, Sumatriptan 25mg, 50mg and 100mg Tabs; Changes to the NLPDP Benefit Listing: New open benefits for D-Forte Capsules, Cortimyxin Opthalmic Ointment; Special Authorization: Sprycel 20mg,50mg, 70mg for CML, Novo-Enoxaparin, Pegasys 180ug injection for Hepatitis C; New Special Authorization Pre Approval Coverage: Norvasc 5mg and 10mg; The following special authorization medications have new coverage criteria: Femara 2.5mg for Breast Cancer, Arimidex 1mg for Breast Cancer, Aromasin 25mg for Breast Cancer, Carvediol 3.125mg, 6.25mg, 12.5mg, and 25mg for stable symptomatic heart failure, VFend 50mg and 200mg for culture proven invasive candidiasis.
Posted February 12, 2008
New Brunswick
Benefit Changes to NBPDP, Bulletin #708, Feb 11, 2008
Highlights
Regular Benefit Additions: ASA ECT 81mg Tab, Equate Daily Low Dose EC 81mg Tab, Exact Coated Daily Low Dose ASA 81mg Tab, Rexall Coated Daily Low Dose ASA 81mg Tab; Special Authorization Additions: Dasatinib (Sprycel) 20mg, 50mg, 70mg Tabs, Sorafenib (Nexavar) 200mg Tabs- resubmission, Suniyinib (Sutent) 12.5mg, 25mg, and 50mg Caps- resubmission
Posted February 11, 2008
NIHB
Updates to Drug Benefit List - Winter 2007/2008
Highlights
Additions to the Drug Benefit List- New Open Benefits- Single Source Drug Products - AccuChek Compact Plus Glucometer, Ascensia Breeze 2 Test Strip, DDAVP Melt 120MCG, 240MCG, 60MCG Tab, Reservoir 5xx 1.8ml syringe, Reservoir 7xx 3.0ml syringe, Resultz 50% Solution, Somatulin Autogel 60mg/0.3ml, 90mg/0.3ml and 120mg/0.3ml; Multi-Source Drug Products: 108 Products Added- See list for details; New Limited Use Benefits: Single-Source Drug Products: Orencia 250mg/15ml injection, Ciprodex OTIC Suspension, Campix 0.5mg Tabs, Champix 1mg Tabs, Champix Starter Pack; Limited Use Benefits- Multi-Source Products: Ran-Tamsulosin 0.4mg SR Caps; Not added to Formulary: Apo Glimepiride 1mg, 2mg, 4mg Tabs, Gen-Zopiclone 5mg Tab, Preg Vit Folic 5, Remicade 100mg/vial injection; Changes in Benefit Staus from Open Benefit to Limited Use: Foradil 12mcg Caps for Inhalation, Oxeze 12mcg/inhalation Turbuhaler, Oxeze 6mcg/inhalation Turbuhaler, Serevent 50mcg/inhalation Diskhaler, Serevent 50mcg/inhalation Diskus; Drugs Discontinued by the Manufacturer: Dimetapp Oral Infant Drop, Duralith 10mg Tab, Endodan 5mg/325mg Tab, Fluotic 20mg Tab, Intal Inhaler, Largactil 40mg/ml injection, Nozinan 5mg, 25mg, 50mg Tab, Orifer F Tab, Premarin 0.9mg Tab, Prexige 100mg Tab, Ratio Aclavulanate 250mg & 125mg Tab, Ratio Aclavulanate 25mg & 6.25mg/ml suspension, Ratio Aclavulanate 50mg & 12.5mg/ml suspension, Ratio Desipramine 25mg and 50mg Tab, Ratio Ipratropium 250 mcg/ml solution, Rhotrimine 75mg caps, Rhotrimine 100mg Tabs, Stemetil 5mg/ml injection, Surgam 300mg SR Caps, Triphasil 21 and 28 Tabs
Posted February 11, 2008
Prince Edward Island
Memorandum: re New MAC List, Feb 4, 2008
Highlights
New Interchangeable/MAC Categories: Ethinyl Estradiol & Cyproterone 0.035mg & 2mg Tab; Products Added to the Interchangeable/MAC List: Apo-Bicalutamide 50mg Tab, Gen-Bicalutamide 50mg Tab, Pms-Temazepam 15mg, 30mg Caps; Discontinued Products: Endodan 5mg Tab, Flomax 0.4mg Controlled Release Cap, Gen-Clomipramine 10mg, 25mg, 50mg Tab, Gen-Diltiazem 30mg, 60mg Tab, Novo-Ramipril 1.25mg Cap, Pms-Alendronate 70mg Tab, Pms- Temazepam 15mg, 30mg Cap
Posted February 11, 2008
Alberta
Additions to AHWDBL, Feb 1, 2008
Highlights
New Drug Products Added to the AHWDBL: New Interchangeable Products Affected by LCA Pricing: Pioglitazone Hydrochloride: Apo-Pioglitazone 15mg, 30mg, 45mg Tab, Ratio-Pioglitazone 15mg, 30mg, 45mg Tab, Sandoz Pioglitazone 15mg, 30mg, 45mg Tab, Raberprazole Sodium: Ran Rabeprazole 10mg, 20mg Oral Enteric Coated Tab
Posted February 11, 2008
Nova Scotia
NS Pharmacare Bulletin Vol #08-02, Feb 2008
Highlights
Changes in Criteria for Clopidogrel (Plavix); Correction to the Criteria for Efalizumab(Raptiva) published in the December Pharmacists Bulletin Vol. #07-11; New Products: Advicor 40/1000 mg Tab, Aricept RDT 5mg Tab, Aricept RDT 10mg Tab, Baraclude 0.5mg Tab, Diovan 320 mg Tab, Humira 40mg/0.8mL Syringe Inj, Humira 40mg/0.8mL Pen, Myozyme 50mg Pdr for Inj, Nexavar 200mg Tab, Novo Olanzapine 2.5mg, 5mg, 7.5mg, 10mg, 15mg Tab, Sebivo 600mg Tab, Sutent 12.5mg, 25mg, 50mg Cap; Changes in Criteria for Bosentan(Tracleer) and Sildenafil(Revatio);
New Diabetic Products: Life Brand Blood Glucose Testing System, Life Brand Blood Glucose Test Strips 50/box, 100/box; New MAC Category: Olanzapine Tablets, 2.5mg, 5mg, 7.5mg, 10mg, 15mg Tabs; Removal of Mac Category: Apo-Misoprostol 100mg Tab, Novo-Misoprostol 100mg Tab; Discontinued Products; 80 See list for details.
Posted February 7, 2008
Ontario
ODB Edition #40, Update 9, effective Feb 12, 2008
Highlights
New Single Source Drugs: Diovan 320mg Tab; Resultz 50% Top Sol 120ml, 240ml; Tri-Cyclen Lo 3 Phase Tab 21Pk, 28Pk. New Multi-Source Drugs: Novo-Atenolthalidone 50 & 25mg, 100 & 25mg Tab; PMS-Bisoprolol 5mg, 10mg Tab; PMS-Enalapril 2.5mg, 5mg, 10mg, 20mg Tab; PMS-Pioglitazone 15mg, 30mg, 45mg Tab. Manufacturer Requested Discontinued Drugs: Novo-Misoprostol 100mcg Tab; Nozinan 25mg/ml Inj Sol 1ml Pk. Delisted Drug: Novo-Ramipril 1.25mg Cap. Price Changes: 37 in total - see bulletin for details. Discontinued Drugs: Endodan 5mg & 325mg Tab; Fucidin Leo Suspension 49.2mg/ml Orl Susp; Pondocillin 35mg/ml O/L. Off Formulary Interchangeable: Apo-Fluoxetine 10mg Cap; Apo-Gemfibrozil 600mg Tab; Gen-Fluoxetine 10mg Cap; Gen-Gemfibrozil 600mg Tab; Novo-Fluoxetine 10mg Cap; Novo-Gemfibrozil 600mg Tab; PMS-Diclofenac K 50mg Tab; PMS-Fluoxetine 10mg Cap; PMS-Gemfibrozil 600mg Tab; PMS-Terbinafine 250mg Tab; Ratio-Fluoxetine 10mg Cap; Sandoz Fluoxetine 10mg Cap.
Posted January 23, 2008
New Brunswick
Benefit Changes to NBPDP, Bulletin #705, Jan 22, 2008
Highlights
Special Authorization Additions: Adalimumab 40mg/ml Prefilled syringe, Prefilled pen; Darbepoetin 10mcg, 20mcg, 30mcg, 40mcg, 50mcg, 60mcg, 80mcg, 100mcg, 130mcg, 150mcg, 200mcg, 300mcg, 500mcg Singleject Prefilled syringe; Efalizumab 150mg Vial; Epoetin Alfa 1000iu/0.5ml, 2000iu/0.5ml, 3000iu/0.3ml, 4000iu/0.4ml, 5000iu/0.5ml, 6000iu/0.6ml, 8000iu/0.8ml, 10000iu/ml, 20000iu/ml, 40000iu/ml Vial, Prefilled syringe; Lanreotide Acetate 60mg, 90mg, 120mg Prefilled syringe. Special Authorization Revised Criteria: Bosentan 62.5mg, 125mg Tab. Drugs Reviewed and Not Listed: Bupropion 150mg, 300mg Tab ER; Lumiracoxib 100mg Tab; Varenicline 0.5mg, 1mg Tab.
Posted January 22, 2008
Nova Scotia
NS Pharmacare Bulletin Vol #08-01, January 2008
Highlights
New Pharmacare Reimbursement List effective February 14, 2008: Discontinued: Acetylsalcylic Acid 325mg & Oxycodone 5mg Tab -Endodan, Amoxicillin & Enzyme Inhibitor 250mg Tab- Clavulin & ratio-Aclavulanate, Ceftriaxone 2g/vial Inj- Rocephin, Desonide 0.05% Crm- Desocort, Imipramine 25mg Tab- Tofranil, Ketoconazole 2% Crm- Nizoral, Lithium 300mg SR Tab, Duralith, Oxybutynin 1mg/ml O/L- Ditropan; Manufacturer Shortage of Lowest Priced Brand: Azithromycin Pos 100mg Tab- Zithromax, Clonidine 0.025mg Tab- Dixarit, Enalapril 10mg & HCTZ 25mg Tab- Vaseretic; New Special MAC Categories: Ketoprofen 50mg Cap, Ketoprofen 50mg, 100mg EC Tab, Ketoprofen 200mg SR Cap, Naproxen 125mg Tab, Meloxicam 7.5mg Tab, Ondansetron 4mg Tab; Increased to Selected MAC: Amoxicillin 250mg, 500mg Cap, Amoxicillin 25mg/ml, 50mg/ml O/L, Cefaclor 500mg Tab, Cephalexin Monohydrate 250mg, 500mg Tab, Cloxacillin 250mg, 500mg Cap, Cloxacillin 25mg/ml O/L, Penicillin V Potassium 300mg Tab, Penicillin V Potassium 60mg/ml O/L.
Posted January 17, 2008
Ontario
Edition 40, Update 8A Jan 16, 2008
Highlights
Not a Benefit Drugs: Apo-Cefaclor 375mg/5ml Oral Susp; Gen-Amoxicillin 250mg cap, 500mg cap; Novo-Cefaclor 250mg, 500mg Cap; Novo-Lexin 250mg, 500mg Tab. Status change from Not a Benefit to General Benefit: Apo-Cefaclor 250mg, 500mg Cap; Apo-Cephalex 350mg, 500mg Tab; Novamoxin 250mg, 500mg Cap. Price changes: 20 in total - see bulletin for details
Posted January 9, 2008
Prince Edward Island
PEI Memorandum, New MAC List
Highlights
New Interchangeable/MAC Categories: Atenolol & Chlorthalidone 25mg and 50mg Tab, Atenolol & Chlorthalidone 25mg and 100mg Tab, Ethinyl Estradiol & L-Norgestrel 0.02mg and 0.10mg Tab (21day), Ethinyl Estradiol & L-Norgestrel 0.02mg and 0.10mg Tab (28day), Pioglitazone 15mg, 30mg and 45mg Tab; Products Added to the Interchangeable/MAC List: Co Fluconazole 50mg and 100mg Tab, Gen Atenolol 25mg Tab, Gen Metoprolol (type L) 25mg Tab, Pms Bisoprolol 5mg and 10mg Tab, Pms Ismn 60mg Tab; Discontinued Products: Dexasone 0.5mg Tab, Oxybutyn 5mg Tab, Sandoz Risperidone 0.25mg Tab
Posted January 9, 2008
Newfoundland
Newfoundland Labrador Bulletin: Notice re Volume 53 pricing
Highlights
Please note that the mandatory charging of the lowest price (per the price posted in the Volume 53 edition of the Formulary) for the following new categories will come into effect January 15, 2008: New Categories: Apo-Benazepril 5mg, 10mg Tab, Lotensin 5mg, 10mg Tab, Novo-Olanzapine 2.5mg, 5mg, 7.5mg, 10mg, 15mg Tab, Zyprexa 2.5mg, 5mg, 7.5mg, 10mg, 15mg Tab, Ran-Cefprozil 250mg, 500mg Tab, Apo-Cefprozil 250mg, 500mg Tab, Cefzil 250mg, 500mg Tab, Apo-Cefprozil125mg/5ml, 250mg/ml oral susp, Ran-Cefprozil 250mg/ml oral susp, Cefzil 125mg/ml, 250mg/ml oral susp, Portia 21 0.15mg/ 0.03ml, Portia 28 0.15mg/0.03ml, Min-Ovral 21 0.15mg/0.03ml, Min-Ovral 28 0.15mg/0.03ml Tabs, ratio-Fluticasone 50mcg/metered dose Aqueous Spray, Flonase 50mcg/metered dose Aqueous Spray, Apo-Enalapril 2.5mg, 5mg, 10mg, 20mg Tab, Vasotec 2.5mg, 5mg, 10mg, 20mg Tab, Novo-Sumatriptan DF 25mg, 50mg, 100mg Tab, Gen-Sumatriptan 25mg, 50mg, 100mg Tab, Imitrex DF 25mg, 50mg, 100mg Tab; Additions to Existing Categories: Gen-Zopiclone 5mg Tab, Gen-Ondansetron 4mg, 8mg Tab, Gen-Tamsulosin 0.4mg Cap, Sandoz Tamsulosin 0.4mg Cap, Co Topiramate 25mg, 100mg, 200mg Tab, Ran-Pravastatin 10mg, 20mg, 40mg Tab, ratio-Venlafaxine XR 37.5mg, 75mg, 150mg Cap, Sandoz Ramipril 1.25mg, 2.5mg, 5mg, 10mg Tab, Co Ramipril 1.25mg, 2.5mg, 5mg, 10mg Cap, pms-Levetiracetam 250mg, 500mg, 750mg Tab, Apo-Glimepiride 1mg, 2mg, 4mg Tab, Novo-Fenofibrate-S 100mg, 160mg Tab, Apo-Brimonidine 0.2% oph sol, Novo-Citalopram 20mg Tab, pms-ASA EC 325mg Tab; As per the prior notice regarding Volume 53 of the Formulary, please note that for this Volume only the prices of Volume 52, for those products listed in Volume 52, remain in effect until Jan 31st, 2008. New prices reflected in Volume 53, for products that were in Volume 52, comes into effect Feb 1st, 2008
Posted January 9, 2008
Alberta
Quarterly Updates to AHWDBL & AEIIDBS, effective Jan 1, 2008
Highlights
Drug Additions: Pms-Amiodarone HCL 100mg Tab; Apo-Desmopressin 0.1mg, 0.2mg Tab; Novo-Desmopressin 0.1mg, 0.2mg Tab; Apo-Doxy 100mg Tab, Cap; Doxycin 100mg Tab, Cap; Novo-Doxylin 100mg Tab, Cap; Pms-Doxycycline 100mg Tab, Cap; Co Enalapril 2.5mg, 5mg, 10mg, 20mg Tab; Gen-Enalapril 2.5mg, 5mg, 10mg, 20mg Tab; Ratio-Enalapril 2.5mg, 5mg, 10mg, 20mg Tab; Sandoz Enalapril 2.5mg, 5mg, 10mg, 20mg Tab; Apo-Hydro 25mg, 50mg Tab; Portia 21 150mcg & 30mcg Tab; Portia 28 150mcg & 30mcg Tab; Co-Lisinopril 5mg, 10mg, 20mg Tab; Gen-Lisinopril 5mg, 10mg, 20mg Tab; Novo-Lisinopril (Type P) 5mg, 10mg, 20mg Tab; Novo-Lisinopril (Type Z) 5mg, 10mg, 20mg Tab;Ran-Lisinopril 5mg, 10mg, 20mg Tab; Ratio-Lisinopril P 5mg, 10mg, 20mg Tab; Ratio-Lisinopril Z 5mg, 10mg, 20mg Tab; Sandoz Lisinopril 5mg, 10mg, 20mg Tab; Apo-Metoprolol SR 100mg SR Tab, 200mg SR Tab; Gen-Ondansetron 4mg, 8mg Tab; Novo-Ondansetron 4mg, 8mg Tab; Pms-Ondansetron 4mg, 8mg Tab; Ratio-Ondansetron 8mg Tab; Sandoz Ondansetron 4mg, 8mg Tab; Pms-Paroxetine 40mg Tab; Apo-Ramipril 1.25mg, 2.5mg, 5mg, 10mg Cap; Novo-Ramipril 1.25mg, 2.5mg, 5mg, 10mg Cap; Ratio-Ramipril 1.25mg, 2.5mg, 5mg, 10mg Cap; Sandoz Ramipril 1.25mg, 2.5mg, 5mg, 10mg Tab; Gen-Tamsulosin 0.4mg SR Cap; Novo-Tamsulosin 0.4mg SR Cap; Ran-Tamsulosin 0.4mg SR Tab; Ratio-Tamsulosin 0.4mg SR Tab; Sandoz Tamsulosin 0.4mg SR Tab; Co Topiramate 25mg, 100mg, 200mg Tab; Gen-Topiramate 25mg, 100mg, 200mg Tab; Novo-Topiramate 25mg, 100mg, 200mg Tab; Pms-Topiramate 25mg, 100mg, 200mg Tab; Ratio-Topiramate 25mg, 100mg, 200mg Tab; Sandoz Topiramate 25mg, 100mg, 200mg Tab; Apo-Zopiclone 5mg Tab; Co Zopiclone 5mg Tab; Gen -Zopiclone 5mg Tab; Novo-Zopiclone 5mg Tab; Pms-Zopiclone 5mg Tab; Ran-Zopiclone 5mg Tab; Ratio-Zopiclone 5mg Tab; Sandoz Zopiclone 5mg Tab; Special Authorization: Exjade 125mg, 250mg, 500mg Tab; Eprex 20,000U/Syr Inj; Fentanyl Citrate 0.05mg/ml Inj; Somatuline Autogel 60mg/Syr, 90mg/Syr, 120mg/Syr Inj; Apo-Levetiracetam 250mg, 500mg, 750mg Tab; Co-Levetiracetam 250mg, 500mg, 750mg Tab; Pms-Levetiracetam 250mg, 500mg, 750mg Tab; Pegasys 180mcg/ml Inj; Pegasys 180mcg/Syr Inj; Jevity 1.5 Cal Liq; Discontinued Listings: Desocort 0.05% Top Cream; Dexasone 0.5mg Tab; Endantadine 100mg Cap; Endodan Tab; Formulex 10mg Cap; Norpramin 25mg, 50mg Tab; Novo-Hylazin 25mg Tab; Nozinan 5mg, 25mg, 50mg Tab; Ostoforte 50,000 IU Cap; Oxybutyn 5mg Tab; Pms-Tiaprofenic 300mg Tab; Ratio-Aclavulanate 250mg/125mg Tab; Ratio-Desipramine HCL 25mg, 50mg Tab; Ratio-Ipratropium 0.25mg/ml Inh Sol; Tofranil 25mg, 75mg Tab; Triphasil 21day, 28 day Tab
Posted January 9, 2008
Ontario
ODB Edition #40, Update 8, effective Jan 15, 2008
Highlights
New Multi-Source Drugs: Apo-Bicalutamide 50mg Tab; Apo-Lisinopril/HCTZ 20mg & 12.5mg Tab; Apo-Pioglitazone 15mg, 30mg, 45mg Tab; Aviane 21 20mcg & 100mcg Tab-21 Pk; Aviane 28 20mcg & 100mcg Tab-28 Pk; Ceftriaxone 1g/Vial, 2g/Vial inj; Co Fluconazole 50mg, 100mg Tab; Co Pioglitazone 15mg, 30mg, 45mg Tab; Gen-Lisinopril HCTZ 10mg & 12.5mg, 20mg & 12.5mg Tab; Gen-Pioglitazone 15mg, 30mg, 45mg Tab; Novo-Citalopram 40mg Tab; Novo-Lisinopril/HCTZ (Type P0 10mg & 12.5mg, 20mg & 12.5mg Tab; Novo-Lisinopril/HCTZ (Type Z) 10mg & 12.5mg, 20mg & 12.5mg Tab; Novo-Pioglitazone 15mg, 30mg, 45mg Tab; Novo-Rabeprazole EC 10mg, 20mg Tab; Ran-Rabeprazole 10mg, 20mg Tab; Ratio-Pioglitazone 15mg, 30mg, 45mg Tab; Sandoz-Lisinopril HCT 10mg & 12.5mg, 20mg & 12.5mg Tab; Sandoz Pioglitazone 15mg, 30mg, 45mg Tab; Taro-Enalapril 2.5mg, 5mg, 10mg, 20mg Tab; Manufacturer Requested Discontinued Drugs: Combivent 20mcg/100mcg/md Aero Inh; Novo-Citalopram 40mg Tab; Ostoforte 50000iu Cap; Oxybutyn 5mg Tab; Pancrease 4500 & 20000 & 25000 usp SR Cap; Timoptic 0.25% Oph Sol;
127 Drug Benefit Price Changes; Not-A-Benefit Drugs: Apo-Erythro E-C 250mg Ent Pel Cap; NU-Amoxi 250mg, 500mg Cap, 25mg/ml, 50mg/ml O/L; Nu-Cefaclor 250mg, 500mg Cap; Nu-Cephalex 250mg, 500mg Tab; Nu-Cloxi 250mg, 500mg Cap, 25mg/ml O/L; Nu-Pen VK 300mg Tab; Off Formulary Interchangeable Products: Apo-Acyclovir 200mg, 400mg Tab; Apo-Diclo Rapide 50mg Tab; Apo-Feno-Micro 67mg Cap; Apo-Methylephenidate 20mg Tab; Apo-Minocycline 50mg, 100mg Cap; Apo-Naproxen EC 250mg, 375mg, 500mg Ent Tab; Apo-Trimebutine 100mg, 200mg Tab; Gen-Acyclovir 200mg, 400mg Tab; Gen-Minocycline 50mg, 100mg Cap; Gen-Naproxen EC 250mg, 375mg, 500mg Ent Tab; Novo-Acyclovir 200mg, 400mg Tab; Novo-Difenac-K 50mg Tab; PMS-Deferoxamine 500mg/Vial, 2g/vial Inj; PMS-Methylphenidate 20mg Tab; PMS-Naproxen EC 375mg, 500mg Ent Tab; Ratio-Acyclovir 200mg, 400mg Tab; Ratio-Minocycline 50mg, 100mg Cap; Sandoz Diclofenac Rapide 50mg Tab; Sandoz Minocycline 50mg, 100mg Cap; Status Changes from Not-A-Benefit to General Benefit: Portia 21 0.03mg & 0.15mg Tab-21 Pk; Portia 28 0.03mg & 0.15mg Tab-28 Pk.
Posted January 2, 2008
Manitoba
Manitoba Interchangeable Formulary Jan 2, 2008
Highlights
Full Interchangeable Formulary Release.
Posted January 2, 2008
Manitoba
Manitoba Drug Benefits and Interchangeability Formulary Amendments, Bulletin #56 effective Jan 2, 2008
Highlights
Deletions from FB: Mirapex 0.25mg, 0.5mg, 1mg, 1.5mg Tab; Novo-Pramipexole 0.25mg, 0.5mg, 1mg, 1.5mg Tab; pms-Pramipexole 0.25mg, 0.5mg, 1mg, 1.5mg Tab. Additions to RB: Mirapex 0.25mg, 0.5mg, 1mg, 1.5mg Tab; Novo-Pramipexole 0.25mg, 0.5mg, 1mg, 1.5mg Tab; pms-Pramipexole 0.25mg, 0.5mg, 1mg, 1.5mg Tab. Not Recommended: Azilect 0.5mg, 1mg Tab; Cipralex 10mg, 20mg Tab; Denavir 1% cream; Tramacet 37.5mg/325mg Tab; Tysabri 300mg/15ml Inj; Vantas 50mg Inj; Vesicare 5mg, 10mg Tab; Androgel 2.5g, 5g gel. Interchangeable Product Price Changes: Agrylin 0.5mg Cap; Amatine 2.5mg, 5mg Tab; Amaryl 1mg, 2mg, 4mg Tab; Anuzinc 10mg Supp; Apo-Amoxi 250mg, 500mg Cap, 125mg/5ml, 250mg/5ml Susp; Apo-Cefaclor 250mg, 50mg Cap, 125mg/5ml, 250mg/5ml Susp; Apo-Cephalex 250mg, 500mg Tab; Apo-Cloxi 250mg, 500mg Cap, 125mg/5ml Susp; Apo-Pen VK 300mg Tab, 300mg/5ml Susp; Apo-Triazolam 0.125mg, 0.25mg Tab; Apo-Zidovudine 100mg Cap; Arava 10mg, 20mg Tab; Buspar 10mg Tab; Carbolith 100mg Cap; Celexa 20mg, 40mg Tab; Coumadin 1mg, 2mg, 2.5mg, 3mg, 4mg, 5mg, 10mg Tab; Diabeta 2.5mg, 5mg Tab; Famvir 125mg, 250mg, 500mg Tab; Fosamax 5mg, 10mg, 40mg, 70mg Tab; Gen-Amoxicillin 250mg, 500mg Cap; Gen-Sotalol 80mg Tab; Gen-Triazolam 0.125mg, 0.25mg Tab; Glucophage 500mg, 850mg Tab; Imovane 5mg, 7.5mg Tab; Keppra 250mg, 500mg, 750mg Tab; Lasix 20mg, 40mg Tab; Lioresal 10mg, 20mg Tab; Lopressor 50mg, 100mg Tab; Lotensin 20mg Tab; Miacalcin 0.2mcg Nasal Spray; Monopril 10mg,20mg Tab; Myochrysine 10mg/ml, 50mg/ml Amp; Nitrazadon 5mg, 10mg Tab; Nitrolingual 0.4mg Pumpspray; Novamoxin 250mg, 500mg Cap, 125mg/5ml, 250mg/5ml Susp; Novamoxin(low sucrose) 125mg/5ml, 250mg/5ml Susp; Novo-Cloxin 250mg, 500mg Cap, 125mg/5ml Susp; Novo-Ferrousgluc 300mg Tab; Novo-Hydrazide 25mg, 50mg Tab; Novo-Cefaclor 500mg Cap; Novo-Lexin 250mg, 500mgTab, 125mg/5ml Susp; Novo-Pen VK 300mg Tab, 300mg/5ml Susp; Novo-Pramipexole 0.25mg, 0.5mg, 1mg, 1.5mg Tab; Nu-Amoxi 250mg, 500mg Cap, 125mg/5ml, 250mg/5ml Susp; Nu-Cefaclor 500mg Cap; Nu-Cephalexin 250mg, 500mg Tab; Nu-Cloxi 250mg, 500mg Cap, 125mg/5ml Susp; Nu-Pen VK 300mg Tab; Plaquenil 200mg Tab; pms-Amoxicillin 250mg, 500mg Cap, 125mg/5ml, 250mg/5ml Susp; pms-Bisacodyl 10mg Supp; pms-Cephalexin 250mg Tab, 125mg/5ml, 250mg/5ml Susp; Pravachol 10mg, 40mg Tab; Renedil 2.5mg, 5mg, 10mg Tab; Rifadin 10mg, 300mg Cap; Ritalin 10mg, 20mg Tab; Ritalin SR 20mg Tab; Sandoz Anuzinc 0.5% Oint; Sectral 100mg, 200mg, 400mg Tab; Sofracort Oph/Ot Drops; Surgam 300mg Tab; Tegretol 200mg Tab, 100mg, 200mg Chew Tab, 200mg, 400mg CR Tab; Timoptic 0.5% Oph Drops; Tofranil 25mg, 50mg Tab; Trandate 100mg Tab; Trental 400mg Tab; Visken 5mg, 10mg, 15mg Tab; Voltaren 50mg, 100mg Supp, 50mg Tab; Voltaren Rapide 50mg Tab; Voltaren SR 75mg, 100mg SR Tab; Zanaflex 4mg Tab; Zantac 150mg, 300mg Tab; Zorcor 5mg, 10mg, 20mg, 40mg, 80mg Tab.
PMPRB News - Regulations
December 2008 CPI released
PMPRB temporarily suspending mandatory reporting of benefits until June 2009
October CPI is published
PMPRB Newsletter Summary
PPMPRB Publishes New Proposed Guidelines
PMPRB announces that ALL benefits must be filed and included in ATP
Working Group on Price Tests and CGPA Working Group Reports Published; Reminder: Publication of New Proposed Guidelines; Brogan Seminars
PMPRB July Newsletter - Summary
New Notices of Hearing, Adderall XR on Admissibility of Evidence, and Brogan Fall Seminars
PMPRB Annual Report 2007
PMPRB Newsletter Summary
PMPRB Releases Adderall XR Decision
Amendments to Patented Medicines Regulations, Responses to Discussion Paper, Apotex Hearing, and VCUs
PMPRB issues a Notice of Hearing and Notice of Application in regards to Apotex Inc.
Brogan comments on the PMPRB’s January 2008 Discussion Paper (Available in English only)
PMPRB Issues Copaxone Decision
The PMPRB Releases its January 2008 NEWSletter
The PMPRB releases a Discussion Paper on Proposed Changes to its Excessive Price Guidelines and Regulations
PMPRB Club: Federal Court Decision on Pre-Patent Jurisdiction, Actual vs. Forecast CPI, and Exchange Rates December 2007
December 2008 CPI released
|
